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1. Introduction  
Medicinal chemistry is an important field of research where chemistry and pharmacology are 
working together to find relations between chemical structures and their biological effect. 
Chemical structures with pharmacological activity can be naturally occurring and obtained from 
diverse sources like animal or plant material or can be chemically synthesized. To identify and 
characterize such active compounds from huge libraries diverse high-throughput screening 
methods were developed during the last decades. The most promising hits can then be used 
as a lead structure in the design and development of the following pharmaceutical 
development. Usually, the identification of the biological target responsible for the 
pharmacological effect is the first essential step for drug research, which can be an enzyme or 
a membrane-bound protein like receptors or transporters. In possession of such a protein 
structure, it is possible to use computer-based screening methods, which are faster and more 
cost effective.  
For this purpose, two different strategies can be applied during the screenings. First, if the 
exact 3D structure of the designated target bound with a ligand is known, usually from X-ray 
-
the detailed interactions between the ligand and the binding site we can fit various ligands into 
the binding pocket (docking) and calculate the binding affinities as docking scores. By 
comparing these scores, it is possible to create a new structure with possible similar or even 
better affinity for the target.[1] As the second method, the -  can be 
used, if the target structure is not known. In this case, the design of new active compounds is 
based on the physiochemical properties of known ligands, from which a pharmacophore model 
is generated to describe the interactions between ligand and target. Through this model, 
suitable substance libraries can be screened (in silico) to find new active compounds, which 
can be later synthetized and evaluated in biological tests.[2] 
The so discovered most active compounds (hits) can be selected to aid as the parent structure 
for further optimization (lead structure). Through stepwise chemical modifications and 
screening of the modified structures, the goal is to find the optimal chemical and physiological 
properties to acquire more potent and/ or more selective active compounds to the target. The 
obtained evaluation results can be used to set up a structure-activity relationship (SAR) to 
support the further optimization of the selected lead structure. 
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1.1. CNS and GABA related diseases 
The central nervous system (CNS) can be involved in a wide-ranging variety of diseases. 
These neurological disorders can include dementia, depression, epilepsy, multiple sclerosis, 
[3,4,5,6,7] The most widespread from them is 
epilepsy, affecting over 50 million patients worldwide.[8] More than 15 different antiepileptic 
drugs can be used for its treatment, but in many cases the medication is not helping or causing 
significant side effects, making the research for new, more effective drugs necessary.[9,10]  
An important cause of these diseases is a disturbance in the GABAergic neurotransmission in 
the CNS. The most important inhibitory neurotransmitter in the CNS -aminobutyric acid 
(GABA, 1) is depicted in Figure 1.[11] Its role, function, and possible ways to influence GABA 
levels in the CNS will be discussed in the following section.  
 
 
 
GABA (1)  
Figure 1. The -aminobutyric acid (GABA) neurotransmitter.  
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1.1.1. GABA neurotransmission 
During the biosynthesis of GABA, glutamate (GLU) is decarboxylated by glutamic acid 
decarboxylase (GAD) in the presynaptic neuron. The formed GABA is transported and stored 
into vesicles by the vesicular transporter (VGAT) from where it is released into the synaptic 
cleft upon depolarization. In the synaptic cleft, GABA can interact with two different GABA 
receptors at the pre- and post-synaptic side, as it is presented in Figure 2. One type, the 
ionotropic GABAA receptors are located on the postsynaptic side and mediate fast signal 
transduction as ligand controlled chloride channels. The second type, the metabotropic GABAB 
receptors, belong to the G-protein coupled receptors (GPCR) and can be found on the pre- 
and post-synaptic side and on the surrounding glial cells as well.[5,12,13,14]  
 
Figure 2. GABA neurotransmission pathways according to literature.[14]  
If GABA binds to the GABAA receptor, the excitability of the neuron is reduced caused by the 
hyperpolarization of the postsynaptic neuron through the influx of chloride ions. Presynaptic 
GABAB receptors play an important negative feedback role to regulate the further release of 
GABA. Postsynaptic GABAB receptors affect hyperpolarization through the efflux of 
potassium.[15]  
The GABA transporter proteins (GATs) are responsible for the termination of the GABAergic 
signaling. They remove the GABA from the synaptic cleft via reuptake into the presynaptic 
neuron where it is stored in vesicles. Another way is by the uptake into the surrounding glial 
cells, where it can be broken down into succinic semialdehyde (SSA) by GABA transaminase 
(GABA-T).[16,17,18] 
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1.1.2. Treatment possibilities and side effects 
An imbalance of the excitatory and inhibitory neurotransmitter levels in the CNS can result from 
reduced GABAergic signaling which is the main reason for epilepsy and the CNS diseases 
mentioned before. To increase GABA levels in the CNS, thus restoring the balance between 
excitatory and inhibitory neurotransmitter, the different GABA receptors, GABA transporters 
(GATs), and the GABA decomposing transaminase can be targeted with therapeutically active 
compounds (Figure 3).  
Benzodiazepines, like diazepam (2), are positive allosteric modulators of the GABAA receptors. 
They bind to a specific allosteric side which results in a conformational change of the receptor, 
thus increasing the opening frequency of the chloride channels.[19,20]  
The GABAB receptors can be influenced by the binding of an agonist molecule, like 
baclofen (3), which increases the GABA neurotransmission.[13] Vigabatrin (4) achieves the 
same effect, through the irreversible inhibition of the GABA transaminase (GABA-T). Most 
relevant to our work is the inhibition of the GABA transporters (GATs) which results in an 
increased GABA level since it is not removed from the synaptic cleft. Tiagabine [(R)-5] acts as 
a selective inhibitor of the GABA transporter subtype 1 (GAT1) and is the only approved 
antiepileptic drug on the market from this category.[9]  
 
 
 
 Diazepam (2)   Baclofen (3)         Vigabatrin (4)      Tiagabine [(R)-5)] 
Figure 3. Approved drugs with an influence on GABAergic neurotransmission.  
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1.2. GABA transporters 
Transporters (solute carriers), in general, make the transport of ions and larger molecules like 
amino acids and neurotransmitters through the cell membrane possible. The GABA 
transporters (GATs) belong to the solute carrier 6 (SLC6) gene family which includes 20 
different transporter subtypes. These, according to their amino acid sequence, can be 
separated into four main subtypes: monoamine transporters, GABA transporters, and two 
groups of amino acid transporters as shown in Figure 4.[21]  
This class of transporters are also termed the neurotransmitter-sodium symporter (NSS) family 
or Na+/Cl- dependent transporters. They use the co-transport of Na+ and Cl- ions in order to 
transport neurotransmitters into the cells against their concentration gradient.[22]  
 
 
 
Figure 4. The SLC6 transporter family tree according to literature.[21]  
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1.2.1. GAT subtypes 
The GABA transporters exist in different subtypes and multiple terminologies are applied to 
name them (Table 1). Within the body, four subtypes can be determined. The origin of the 
transporter from which animal it was cloned can also play a significant role. Additionally, the 
terms for the human transporters, but it 
is often used for all species. During our research, we used only GAT transporters cloned from 
mice (mGAT1 mGAT4).[23,24]  
 
 
Table 1. Different nomenclatures of the GATs. 
Source GAT subtypes 
mouse mGAT1 mGAT2 mGAT3 mGAT4 
human hGAT-1 hBGT-1 hGAT-2 hGAT-3 
HUGO GAT1 BGT1 GAT2 GAT3 
 
 
GAT1 is primarily located in the presynaptic neurons of the CNS and plays a crucial role in the 
transport of GABA. Studies have shown that BGT1 and GAT2 are mainly located in the kidneys 
and liver, thus playing only a minor function in the GABAergic neurotransmission. Another 
important subtype is GAT3. It is located on the glial cells surrounding the neurons of the CNS 
and is responsible for the uptake of GABA into the glial cell where it is metabolized afterwards. 
[17,25,26] 
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1.2.2. Structure and transport mechanism of SLC6 transporters  
The structure of the NSSs was extensively studied in the last few decades and as a result the 
isolation, the amino acid sequence analysis, and the cloning of the GAT1 NSS were 
accomplished.[27] These results and the successful crystallization and X-ray structure analysis 
of the leucine transporter (LeuTAa) from the bacteria Aquifex aeolis in the presence of the 
substrate leucine and two sodium ions confirmed the structure of the transporter as illustrated 
in Figure 5.[28]  
However, the overall amino acid sequence of the LeuTAa compared to the sequence of the 
eukaryotic SLC6 transporters is only 20%  25%, but in the region of the substrate binding site, 
the homology in the sequence is significantly higher 55%  67%.[29] This fact, in general, 
makes the use of this structure valid for the understanding of the assembly and purpose of 
these transporters.  
 
 
  
Figure 5. Structure of the LeuTAa transporter.[28]  
The transporter LeuTAa contains 12 transmembrane helices (TMs) which are connected by 
corresponding loops both intra- and extracellularly (IL and EL), and the amino- and the 
carboxyl-terminus is located on the intracellular side (Figure 5). The primary binding site (S1) 
of leucine and the two sodium ions has a funnel-like structure, consisting from an inner ring 
formed by TM1, TM3, TM6, and TM8 and an outer ring formed by TM2, TM4, TM5, TM7, TM9, 
and TM10 (Figure 5). Two transmembrane helices (TM1 and TM6) have an interruption in their 
helical structures directly at the binding site, thus are divided into two parts (a and b) so the 
formation of hydrogen and ionic bonds between the exposed amino groups and carbonyl 
groups is made possible.[28]  
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Model, in which the transporter goes through several conformational changes.[30] Initially, the 
transporter is open to the extracellular side and is ready to accept the ligand and ions at the 
binding site (S1). After the substrate has bound to t - conformation, the 
outward-occluded  as 
shown in Figure 6. Subsequently, the intracellular gate opens and the substrate is released 
rd- [31]  
 
 
Figure 6. Postulated transport mechanism of the NSSs.[31] 
Molecular-dynamic simulations and further studies have shown that a second binding site (S2) 
located just above the extracellular gate of LeuT exists. It is stated that the occupation of this 
binding site is necessary for the allosteric release (S1) of the substrate into the cytoplasm.[32] 
This statement is still debated because others have shown that S2 is rather a binding pocket 
for non-competitive LeuT inhibitors or detergents, which prevent the conformational change of 
the transporter.[33,34] Further X-ray crystallographic structures of other NSSs supported the 
findings of the LeuT results.[35,36] The structure of the eukaryotic dopamine transporter (DAT) 
bound with the tricyclic antidepressant nortriptyline was isolated from Drosophila melanogaster 
and this was in perfect accordance with the prokaryotic LeuT structure. Similarly, the structure 
of the human serotonin transporter (SERT) in complex with the antidepressant (S)-citalopram 
or paroxetine was also published which demonstrates how the binding to the S2 site sterically 
hinders the release of the ligand from the central binding side.[37]  
  
 Introduction 9 
1.2.3. GATs as drug targets  
Since the GATs are involved in many neurological disorders mentioned before, their inhibition 
offers a viable way for a treatment by restoring the physiological neurotransmitter balance in 
the CNS. 
To this end, researchers are looking for compounds that inhibit the GABA uptake effectively, 
but do not bind to the GABA receptors. First, acyclic analogs of GABA were developed, but 
these compounds showed no selectivity for any of the GAT subtypes and additionally acted as 
ligands for the GABAA receptor. Then, cyclic amino acids like guvacine (6) and nipecotic acid 
(rac-7) presented more promising results and became a new starting point for GAT inhibitor 
development.[38] The inhibitory potencies of these compounds (6 and rac-7) are similarly high 
without any pronounced selectivity (Table 2). It is worth to mention that the (R)-enantiomer of 
nipecotic acid [(R)-7] is significantly more potent than the (S)-enantiomer [(S)-7] at all mGATs. 
The corresponding pIC50 values are listed in Table 2 and range from 3.13 to as high as 5.12.  
 
Table 2. Small, cyclic amino acids as GABA analogs.  
 
   Guvacine (6)          Nipecotic acid (rac-7)   
Compound 
GABA uptake inhibition (pIC50 ± SEM)a 
mGAT1 mGAT2 mGAT3 mGAT4 
6 4.87 ± 0.06 3.31 ± 0.03 4.59 ± 0.05 4.59 ± 0.05 
rac-7 4.88 ± 0.07 3.10 ± 0.09 4.64 ± 0.07 4.70 ± 0.07 
(R)-7 5.12 ± 0.03 3.40 ± 0.05 4.76 ± 0.05 4.95 ±0.05 
(S)-7 4.24 ± 0.05 3.13 ± 0.14 3.83 ± 0.04 3.63 ± 0.06 
aFor sake of comparability all listed functional inhibitory potencies (pIC50 values) derive from the biological test of 
our research group (GABA uptake assay based on HEK293 cells stably expressing the different mGATs). 
 
On the other hand, these compounds are highly polar and under physiological conditions 
present in a zwitterionic state, making the penetration of the blood-brain-barrier (BBB) 
extremely difficult. To overcome this problem, lipophilic side chains were introduced at the 
nitrogen atom of the heterocycles resulting in not only more potent compounds, but also more 
subtype selective derivatives at the GATs.[39,41,42,51,52] The applied modifications and their 
results will be discussed in the following part. 
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1.2.3.1. mGAT1 selective inhibitors  
The substitution of the nitrogen atom of the before mentioned heterocyclic amino acids 
(6 and rac-7) with a linker to a lipophilic moiety, leads to highly potent mGAT1 selective 
compounds as it is shown in Table 3. The flexible linkers can have a length of four or five atoms 
with a double bond in it and two aromatic residues at the end. Amongst these compounds, 
tiagabine [(R)-5] is used as an add-on treatment of partial epilepsy.[40]  
 
 
Table 3. Selective inhibitors of mGAT1.  
 
 SKF-89976A (8) [39]       Tiagabine [(R)-5] [41]   NO711 (9) [42] 
Compound GABA uptake inhibition (pIC50 ± SEM)
a 
mGAT1 mGAT2 mGAT3 mGAT4 
8 6.16 ± 0.05 3.43 ± 0.07 3.71 ± 0.04 3.56 ± 0.06 
(R)-5 6.88 ± 0.12 50%b 64%b 73%b 
9 6.83 ± 0.06 3.20 ± 0.09 3.62 ± 0.04 3.07 ± 0.05 
aFor sake of comparability all listed functional inhibitory potencies (pIC50 values) derive from the biological test of 
our research group (GABA uptake assay based on HEK293 cells stably expressing the different mGATs). 
bRemaining 3[H]GABA-Uptake in the presence of 100 µM test compound. 
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To improve the former results, Andersen conducted a series of SAR studies. This led to the 
discovery of even more potent inhibitors of GAT1 (Figure 7) which had an ether function in the 
linker and a 2-biphenyl [(R)-10] or 2-benzylphenyl [(R)-11] residue at the end.[43,44]  
A recent study demonstrated how the exchange of the alkoxyalkyl spacer of (R)-10 with a 
but-3-en-1-yl linker resulting in rac-12 delivered a similar inhibitory activity at mGAT1 (Figure 
7) which can be viewed as a new parent structure for the further development of mGAT1 
inhibitors. However, the same modification applied to (R)-11 caused an order of magnitude 
drop in the inhibitory potency at mGAT1 for rac-13.[45]  
 
 
 
   (R)-10    (R)-11    rac-12   rac-13  
   pIC50 = 6.96    pIC50 = 6.99   pIC50 = 6.79 ± 0.12 pIC50 = 5.72 ± 0.04 
Figure 7. New generation of GAT1 selective inhibitors.[44,45]  
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1.2.3.2. Selective inhibitors of mGAT2 
Contrary to the mGAT1 inhibitors, the today existing mGAT2 inhibitors lack the potency and 
selectivity for their target. The known best mGAT2 inhibitor NNC05-2090 (14, Table 4) [46] is 
only with a factor of 10 more potent at mGAT2 than at the other GATs. The mixed 
mGAT1/mGAT2 inhibitor EF1502 (15) [47] was derived from the weak mGAT1 inhibitor 
N-methyl-exo-THPO (16),[48] which is slightly more potent at mGAT1 and has no noteworthy 
inhibition at mGAT3 or at mGAT4. 
Interestingly, compared to the potent mGAT1 inhibitors with a cyclic amino acid residue, 
NNC05-2090 (14), as the most potent mGAT2 inhibitor, does not have a carboxylic acid moiety, 
which implies that the strong binding to mGAT2 is the result of the suitable parent structure of 
the compound.  
 
 
Table 4. Selective inhibitors of mGAT2.  
 
 
 
 
 
  NNC05-2090 (14) [46]  EF1502 (15) [47]   N-Methyl-exo-THPO  
         [(R)-16] [48] 
Compound GABA uptake inhibition (pIC50) 
mGAT1 mGAT2 mGAT3 mGAT4 
14 4.72a 5.85a 4.39a 4.82a 
15 5.15b 4.59b < 3.52b < 3.52b 
(R)-16 3.35b < 2.52b < 2.52b < 2.52b 
apKi values. bNo SEM values in the literature.  
 
  
 Introduction 13 
1.2.3.3. mGAT3 and mGAT4 selective inhibitors 
A series of amino acids were tested in our research group for their potency at and selectivity 
for the mGATs (Table 5).[49] This showed that compound (Z)-4-amino-2-butenoic acid (17) is 
significantly more potent at mGAT3 mGAT4 than at mGAT1 mGAT2. Originating from the 
known mixed mGAT3 mGAT4 inhibitors beta-alanine (18) and 2,3-diaminopropanoic 
acid (19), we managed to find two new potent parent structures. Of these, isoserine (20) 
proved to be one of the most potent and selective mGAT3 mGAT4 inhibitor with a clear 
subtype selectivity (factor > 400) compared to mGAT1 mGAT2. Furthermore, (2-amino-1,3-
thiazol-4-yl)acetic acid (21) was found to be the first mGAT3 selective inhibitor despite its low 
potency (pIC50 = 3.36). Additionally, 3-imidazol-2-yl-propionic acid (22) was found to be even 
more potent at mGAT3, while having similar subtype selectivity.[50]  
 
 
Table 5. Amino acids with mGAT3 and mGAT4 selectivity from the literature.[49,50] 
 
   17   18    19    20  
 
 
      21    22  
Compound GABA uptake inhibition (pIC50 ± SEM)
a 
mGAT1 mGAT2 mGAT3 mGAT4 
17 2.99 ± 0.04 3.67 ± 0.08 4.95 ± 0.04 4.93 ± 0.09 
18 2.59 ± 0.03 3.48 ± 0.11 4.66 ± 0.06 4.46 ± 0.13 
19 3.11 ± 0.02 3.50 ± 0.12 4.66 ± 0.08 5.05 ± 0.02 
20 2.33 ± 0.05 3.39 ± 0.11 4.87 ± 0.05 4.78 ± 0.14 
21 98%b 77%b 3.36 ± 0.11 55%b 
22 63%b 3.28 ± 0.12 4.54 ± 0.15 3.51 ± 0.03 
aFor sake of comparability all listed functional inhibitory potencies (pIC50 values) derive from the biological test of 
our research group (GABA uptake assay based on HEK293 cells stably expressing the different mGATs). 
bRemaining 3[H]GABA-Uptake in the presence of 1 mM test compound.  
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Based on the weak, non-selective GAT inhibitor EGYT-3886 (23, Table 6), a series of new 
compounds was developed, which included the most potent and selective mGAT4 inhibitor 
(S)-SNAP 5114 [(S)-24].[51] From this research, it seemed that the key structural elements 
needed for the mGAT4 selectivity were a C2-spacer connected via an ether function to a 
methoxy-substituted trityl residue. Further research conducted in our group resulted in the 
similarly potent and selective DDPM-1457 [(S)-25] in which the ether function of the linker was 
replaced by a trans-alkene unit. This modification additionally significantly increased the 
compounds chemical stability compared to (S)-SNAP 5114 [(S)-24].[52] 
 
 
Table 6. GABA uptake inhibitors for mGAT3 and mGAT4. 
 
EGYT-3886 (23) [51]        (S)-SNAP-5114 [(S)-24] [51]  DDPM-1457 [(S)-25] [52] 
 
Compound GABA uptake inhibition (pIC50 ± SEM) 
mGAT1 mGAT2 mGAT3 mGAT4 
23a 4.59b 4.41c 4.52d 4.34e 
(S)-24f 4.07 ± 0.09 63%g 5.29 ± 0.04 5.71 ± 0.20 
(S)-25f 4.40 ± 0.05 4.42 ± 0.11 5.47 ± 0.02 5.87 ± 0.08 
aInhibitory potencies derive from literature [51]; bhGAT1; chBGT1; drGAT2; ehGAT3; fFor sake of comparability the 
indicated functional inhibitory potencies (pIC50 values) derive from the biological test of our research group (GABA 
uptake assay based on HEK293 cells stably expressing the different mGATs); gRemaining 3[H]GABA-Uptake in the 
presence of 100 µM test compound.  
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2. Aims and scope  
Antiepileptic drugs that are currently on the market do not always provide a satisfactory 
treatment for patients. Hence, there is an urgent need for new, more modern treatment 
options.[10] The GATs represent a good target for the development of new inhibitors which 
would selectively target only one of the GAT subtype present in the CNS. This leads to the 
objective of this study, to find inhibitors of the mGAT4 transporter with high potency and 
selectivity for its target.  
 
2.1. Development of N-substituted nipecotic acid derivatives as selective 
mGAT4 reuptake inhibitors 
During an earlier study in our group, DDPM-1457 [(S)-25] a carba-analog of the known 
(S)-SNAP-5114 [(S)-24] GAT inhibitor with moderately high potency at and selectivity for 
mGAT4 was discovered.[52] The carba-analog (S)-25 has a trans-alkene moiety in the spacer 
between the nipecotic acid and the lipophilic residue instead of an ether functionality, 
compared to (S)-24. Additionally to the similar potencies at and selectivity for the mGATs, the 
new compound exhibited greatly increased chemical stability. This hit compound directed our 
following research to explore the base structure by its modification in multiple different ways to 
find even better and more selective inhibitors for mGAT4.  
For the first new carba-analog family, the alkyne-analogs (rac-26, Figure 8), we were interested 
how the inhibitory potencies and selectivity is influenced if the trans-alkene moiety of 
DDPM-1007 (rac-25),[52] the racemic analog of the enantiopure DDPM-1457 [(S)-25], is 
converted into a triple bond. Further modifications aimed to introduce a series of different 
residues, like aromatic and heteroaromatic rings, benzylic residues or sterically less 
demanding groups at the lipophilic moiety (Figure 8) and to lengthen the spacer by one 
methylene group on either side of the alkyne unit.  
 
   DDPM-1007 (rac-25)         rac-26  
Figure 8. General structure of the alkyne-analogs of DDPM-1007 (rac-25). For residues R1, R2, m, and n see 
Publication 1.  
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During the following project, we applied the identical lipophilic moieties from the alkyne-
analogs (rac-26, Figure 8) to the original structure with the trans-alkene spacer (rac-25) to see 
if it leads to positive results in the biological evaluation of compound rac-28. Additionally, while 
keeping the spacer unmodified, three identical heterocyclic residues were introduced to the 
lipophilic end (rac-27), replacing all of the previous 4-methoxyphenyl residues (Figure 9).  
 
 
  rac-27           DDPM-1007 (rac-25)              rac-28 
Figure 9. Additional trans-alkene analogs. For residues R1, R2, Het, and n see Publication 2.  
 
 
The topic of the last part included the synthesis and biological evaluation of cis-alkene analogs 
(rac-29), in which the alkyne analogs (rac-26) were converted via catalytic hydrogenation to 
the corresponding cis-alkene derivatives to complete all of the planned modifications for the 
carba-analog (S)-25 (Figure 10).  
 
 
   DDPM-1007 (rac-25)   rac-29  
Figure 10. General structure of the cis-alkene analogs. For residues R1, R2, m, and n see Publication 3.  
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2.2. Coupling methods 
For the synthesis of the targeted analogs, we utilized the reaction of an iminium salt with 
diverse organomagnesium or organozirconium reagents. Similar reactions are well reported 
and known to provide the desired products selectively, under mild conditions, and with high 
yields.[53,54,55,56,57]  
 
2.2.1. Iminium salts 
An iminium salt or iminium cation has the general structure 32 (Scheme 1). The condensation 
of a primary amine (30, R2 = H) with a ketone/ aldehyde (31) leads to an equilibrium, in which 
the imine form (33) is generated and under acidic conditions exists as iminium ion (32). A 
secondary amine (30, R2  H) can also form with an aldehyde or ketone an iminium ion (32) 
and they can be isolated as salts of strong acids.[58]  
 
 
 30     31    32           33 
Scheme 1. Formation of iminium ions and imines. 
 
Alternatively, the reaction of aminoacetal 34 with TMSCI (35) under water-free conditions 
(Scheme 2) produces iminium salt 36 and TMS-amine 37.[59] Additionally, the treatment of 
N,O-acetal 38 with methyltrichlorosilane 39 easily forms iminium salt 40 and silyl ether 
derivative 41 as a side product.[60] A similar, alternative method would be more suitable for 
our conditions, due to the sensitivity of the organometallic reagents planned to be used as 
nucleophiles.  
 
 
  34   35               36         37 
 
 
  38   39              40         41 
Scheme 2. Alternative iminium ion formations under water-free conditions.[59,60]  
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2.2.2. Hydrozirconation 
The addition reaction in which an organozirconium compound is attached across a double or 
triple bond is the hydrozirconation. The sterically shielded carbon-zirconium bonds of 
organozirconocenes possess a highly functional group tolerance and can be used for 
transmetalation reactions.[61] One of the most common methods to generate 
organozirconocene reagents (43 and 46) is the reaction between alkynes 42 or alkenes 45 
with Schwartz  reagent 44 (Cp2ZrHCl, Scheme 3), to give 43 and 46 respectively.[61,62] The 
ionic character of the C Zr bond, according to the Pauling electronegativity scale, is almost 
equivalent to the C Mg bond, but they exhibit a substantially weaker nucleophilic character 
due to the steric shielding from the two cyclopentadienyl ligands. For synthetic applications, 
the most widely used organozirconium compounds are the alkenylzirconocenes 43. They are 
easily accessible and their synthesis from alkynes and Schwartz  reagent is fast, 
regioselective and reasonably functional group tolerant.  
 
 
 
      42   43  
 
 
  44    45   46   
Scheme 3. Formation of alkenyl- and alkylzirconocenes by hydrozirconation.  
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3. Summary of manuscripts and published results 
3.1. First publication: 
Synthesis and biological evaluation of novel N-substituted nipecotic 
acid derivatives with an alkyne spacer as GABA uptake inhibitors  
In recent years, the search for GABA uptake inhibitors with high affinity and subtype selectivity 
led to the discovery of the N-substituted nipecotic acid derivative DDPM-1457 [(S)-25], which 
holds good affinity and selectivity for its target mGAT4. As a carba-analog of the known 
(S)-SNAP-5114 [(S)-24], it only differs at its spacer between the nipecotic acid and the lipophilic 
residue which has a trans-alkene unit instead of an ether functionality, respectively.  
In this study, we report our efforts to expand the knowledge about the structure-activity relation 
(SAR) of the carba-analog family of DDPM-1457 [(S)-25], in pursuit of finding even more potent 
and selective inhibitors for mGAT4. To this end, the planned structural modifications of [(S)-25] 
included the replacement of the trans-alkene moiety of the spacer with an alkyne unit, 
increasing the length of the spacer by one methylene group or substituting one aromatic 
residue at the lipophilic moiety with a heterocyclic, benzylic or sterically less demanding group.  
For the synthesis of the targeted compounds, a suitable method was developed involving 
iminium chemistry. It is well known from the literature that iminium salts readily react with 
organometallic nucleophiles. Thus, we choose to react the in situ generated iminium ion 
derived from the N,O-acetal of nipecotic acid with a series of ethynylmagnesium chloride 
nucleophiles obtained through the deprotonation of the corresponding terminal alkynes with 
nBuMgCl. The required terminal alkynes were produced by the treatment of triaryl chlorides 
with ethynylmagnesium bromide or (trimethylsilyl)ethynyllithium reagents. Under the mild 
coupling conditions (40°C, THF), the yields for the corresponding esters were moderate to 
good (39%  85%). After the final hydrolysis of the esters, the obtained free nipecotic acid 
derivatives were evaluated for their inhibitory potency at and selectivity for the mGATs. 
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The results of the new alkyne derivatives show, that the introduced small change from a double 
bond into a triple bond in the linker generally caused a significant drop in the potencies 
accompanied by a slight shift in the selectivity from mGAT4 to mGAT1. Increasing the spacer 
length had a similar outcome, potencies and the selectivity got significantly lower than that of 
the parent structure and were comparable to the result of the alkyne analogs with a shorter 
spacer. Interestingly, the alkyne analog with a benzothiophene residue instead of a 
4-methoxyphenyl ring had a reasonably high affinity for all mGATs (pIC50 ~ 5), which may 
indicate that electron rich and planar aryl moieties, similar to a 4-methoxyphenyl residue, can 
be suitable for interaction with the mGAT proteins. 
 
 
 
 
Declaration of contributions: 
Synthesis of the N-substituted nipecotic acid derivatives and all precursor molecules was done 
by myself including evaluation of the analytical data of all compounds. The practical 
performance of the biological test of all compounds was carried out by the technical assistants 
of the group under the supervision of Dr. Georg Höfner.  
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3.2. Second publication: 
Synthesis and biological evaluation of novel N-substituted nipecotic 
acid derivatives with a trans-alkene spacer as potent GABA uptake 
inhibitors  
Our previous discovery of DDPM-1457 [(S)-25], a chemically more stable analog of 
(S)-SNAP-5114 [(S)-24], was an important step in the search for new and potent mGAT4 
selective inhibitors. Such compounds could provide an additional treatment option for patients 
with GABAergic disturbances, especially in cases where the currently used medications are 
not providing the hoped relief.  
In this present publication, we focus on broadening the knowledge about this carba-analog 
family in order to find even better inhibitors for mGAT4. To this end, we modified the parent 
structure of DDPM-1007 (rac-25), the racemic analog of the enantiopure DDPM-1457 [(S)-25], 
in the following ways. While keeping the trans-alkene spacer unmodified, first, we replaced 
one aromatic ring of the lipophilic moiety by a series of residues, e.g. aromatic, heteroaromatic 
or benzylic residues. Furthermore, the length of the spacer was increased by one methylene 
group by inserting it between the trans-alkene moiety and the lipophilic residue to gain an 
insight on how the spacer length influences the binding affinities. Additional compounds were 
prepared with three larger and identical aromatic moieties, which were hoped to mimic the 
original 4-methoxyphenyl residues.  
For the synthesis of the esters, we utilized the building blocks from our previous publication, in 
which we used the coupling reaction of an iminium salt with an organomagnesium species 
generated from terminal alkynes. Now, we report the coupling reaction between the reported 
iminium salt and diverse zirconocene reagents, generated through the hydrozirconation of a 
series of terminal alkynes. Due to the trans-selectivity of the hydrozirconation step, this reaction 
produces the desired esters with the preferred trans-alkene spacer. The yields are moderate 
to good.  
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After the final hydrolysis of the esters, the obtained free acid derivatives were evaluated for 
their inhibitory potencies at and selectivities for the mGATs. The results are well comparable 
with the parent compound DDPM 1007 (rac-25), however, the new compounds have generally 
lower potencies at mGAT3 mGAT4 and slightly higher at mGAT1. Amongst them, one of the 
best mGAT4 inhibitors, which has a benzothiophene residue at the lipophilic moiety, was also 
synthesized as the pure (S)-enantiomer. As it was expected for this enantiomer, the potencies 
at and selectivities for mGAT3 mGAT4 rose further, making it the most potent compound in 
our present series. Additionally, the observation was made that the direct analog of 
DDPM-1007 (rac-25) with a spacer elongated by one methylene group, by insertion of this 
group between the trans-alkene and the triaryl residue, had a significant lower potency at 
mGAT4. Another compound having a longer spacer and only two phenyl rings at the lipophilic 
moiety was found to exhibit a surprisingly high potency at and selectivity for mGAT1. This 
compound s inhibitory potency (pIC50 = 6.78 ± 0.09) was almost as high as that of tiagabine 
[(R)-5] (pIC50 = 6.88 ± 0.12). Finally, an analog of DDPM-1007 (rac-25) with three identical 
benzofuran rings, instead of 4-methoxyphenyl residues, showed a significantly increased 
binding affinities at all mGATs (pIC50: 5.02  5.39), making it an interesting candidate for 
pharmacological studies.  
 
 
 
 
Declaration of contributions: 
Synthesis of the N-substituted nipecotic acid derivatives and all precursor molecules was done 
by myself including evaluation of the analytical data of all compounds. The practical 
performance of the biological test of all compounds was carried out by the technical assistants 
of the group under the supervision of Dr. Georg Höfner.  
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3.3. Manuscript of the third publication: 
Synthesis and biological evaluation of novel N-substituted nipecotic 
acid derivatives with a cis-alkene spacer as GABA uptake inhibitors  
In order to discover more potent and selective inhibitors for the murine gamma-aminobutyric 
acid transporter 4 (mGAT4), the earlier discovered carba-analog family of DDPM-1007 (rac-25) 
was subjected to extensive modifications. New mGAT4 inhibitors could be useful in the 
treatment of complex neurological disorders (depression, epilepsy, and neuropathic pain), and 
overcome drawbacks (side effects, ineffectiveness in some cases) of the currently used 
medications. The carba-analog rac-25 having similar potency and additionally significantly 
increased chemical stability was obtained through the replacement of the ether function in the 
spacer of the first prototypic mGAT4 inhibitor (S)-SNAP-5114 [(S)-24] by a trans-alkene 
moiety. The present work aimed to uncover how the change from a trans-double bond to a 
cis-double bond in the spacer would affect the inhibitory potency and subtype selectivity.  
For the synthesis of the cis-alkene analogs, we utilized the previously reported alkyne-analogs 
as starting compounds. A catalytic hydrogenation with Lindlar  catalyst produced the desired 
new analogs in a practical and effective way (49%  73%). These analogs, compared to 
DDPM-1007 (rac-25), have a cis-alkene spacer connected to diverse lipophilic moieties, in 
which, one of the original 4-methoxyphenyl residue is replaced by aromatic and heteroaromatic 
cycles, benzylic residues or sterically less demanding groups. Additionally, the spacer length 
was increased by one methylene group either by inserting it between the cis-alkene group and 
the lipophilic residue or between the nipecotic acid and the cis-alkene moiety.  
The biological evaluation of the structure-activity relation (SAR) study revealed that the 
obtained compounds generally show slightly decreased potencies at mGAT1 mGAT3 and a 
significant drop at mGAT4 as compared to the analogous compounds with a trans-alkene 
moiety in the spacer, e.g. DDPM-1007 (rac-25). Increasing the spacer length of the cis-analogs 
with three aromatic residues further decreased the potency at mGAT4, but it showed different 
results at mGAT1. If the additional methylene group was placed between the trityl moiety and 
the cis-alkene unit a surprisingly high inhibitory potency at mGAT1 (pIC50 = 6.00 ± 0.04) was 
observed, which was not evident if the additional methylene group was placed between the 
nipecotic acid and the cis-alkene moiety (pIC50 = 4.39).  
Declaration of contributions: 
Synthesis of the N-substituted nipecotic acid derivatives and all precursor molecules was done 
by myself including evaluation of the analytical data of all compounds. The practical 
performance of the biological test of all compounds was carried out by the technical assistants 
of the group under the supervision of Dr. Georg Höfner.  
 Summary of the thesis 24 
4. Summary of the thesis 
As more and more people are in desperate need of new treatment options and better 
medications for disturbances in the GABAergic neurotransmission-related illnesses (epilepsy, 
 and depression), the search for new inhibitors of the GABA transporter 
proteins is an ongoing challenge. Our goal was to find potent and selective inhibitors of 
mGAT4, by exploring new carba-analog families of the previously reported first prototypic 
mGAT4 inhibitor (S)-SNAP-5114 [(S)-24].  
Our work was done in three steps resulting in three carba-analog families which most 
importantly differ in their spacer incorporating an alkyne, trans-alkene, or a cis-alkene moiety. 
The structure of these new derivatives is closely related to DDPM-1457 [(S)-25], the first 
carba-analog of (S)-SNAP-5114 [(S)-24], in which the ether group of (S)-24 has been replaced 
with a trans-alkene moiety, making it significantly more chemically stable while retaining good 
activity and selectivity for mGAT4. The alkyne-analogs were synthesized through the coupling 
reaction between an iminium ion derived from nipecotic acid and a series of organomagnesium 
species generated from terminal alkynes. The new analogs, compared to DDPM-1007 
(rac-25), the racemic analog of (S)-24, had an alkyne moiety in the spacer and one aromatic 
residue of the triarylmethyl moiety replaced by a wide range of aryl, heteroaryl, benzyl, or 
sterically less demanding group. The biological results show that these modifications caused 
a significant decrease in the mGAT4 potency, of around one log unit, compared to (rac-25). 
Similar results could be observed for the alkyne-analogs, which had a by a methylene group 
longer spacer. Furthermore, one compound having a benzothiophene substituent at the 
lipophilic moiety exhibited heightened inhibitory potencies at all mGATs (pIC50 = 4.92  5.06), 
suggesting that the benzothiophene ring being similar in size and shape, but more rigid and 
electron rich, compared to the original 4-methoxyphenyl moiety, could favor the interaction with 
the mGAT proteins.  
The trans-alkene analog family of DDPM 1007 (rac-25) was broadened with new members. 
For these analogs, the trans-double bond of the spacer was retained while one of the 
4-methoxyphenyl rings was replaced by an aromatic, heteroaromatic, benzylic or sterically less 
demanding group. Additional analogs have their spacer lengthened by one methylene group 
between the trans-alkene moiety and the lipophilic residue, which has three or two 
4-methoxyphenyl or phenyl rings. Further derivatives have not only one, but all three of their 
aromatic moieties replaced by three identical and sterically more demanding heterocyclic 
residues. The synthesis of the new trans-alkene analogs was accomplished through the 
reaction of the before mentioned iminium salt with a series of alkenylzirconocene reagents 
generated via the hydrozirconation of the corresponding terminal alkynes. Compared to 
DDPM-1007 (rac-25) the new analogs generally have similar or distinctly lower potencies at 
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mGAT4 and slightly increased potency at mGAT1. Unfortunately, compounds with a longer 
spacer display an even lower potency at mGAT4. Interestingly, one analog with a longer spacer 
and only two phenyl rings as the lipophilic moiety exhibited surprisingly high potency at and 
selectivity for mGAT1 (pIC50 = 6.78 ± 0.09) which was well comparable to that of tiagabine 
(pIC50 = 6.88 ± 0.12). Additionally, amongst the products with three identical heterocyclic rings, 
one analog having three benzofuran moieties had significantly increased potencies at all 
mGATs (pIC50: 5.02  5.39). Consequently, this analog could be used as a pharmacological 
tool to get a deeper understanding of how the inhibition of multiple GATs at the same time 
affects the GABA levels of the body.  
A further topic of my research was the synthesis of compounds of the cis-alkene analog family 
to compare their biological results with the trans-alkene and the alkyne-analogs. It was 
intended to keep all structural elements identical to the other two analog families, except for 
the configuration of the double bond in the spacer, to allow an easy side-by-side comparison. 
In order to gain easy access to the desired cis-alkene analogs, I used the alkyne derivatives 
from our previous work as starting material and subjected them to a partial catalytic 
hydrogenation r . The structure-activity relationship (SAR) study 
of the cis-alkene analogs having one 4-methoxyphenyl residue replaced, compared to 
DDPM-1007 (rac-25), by aromatic, heteroaromatic, benzylic or sterically less demanding 
groups revealed, that the inhibitory potency, in general, slightly decreased at mGAT1 mGAT3 
and was significantly reduced at mGAT4. Additionally, the potency at mGAT4 got even lower 
for the cis-alkenes with an increased spacer length, regardless of the position of the additional 
methylene group. Interestingly, if the analog with three phenyl rings at the lipophilic moiety had 
the additional CH2-group between the trityl moiety and the cis-alkene unit the potency at 
mGAT1 was significantly higher (pIC50 = 6.00 ± 0.04) than if it is between the nipecotic acid 
residue and the cis-alkene group (pIC50 = 4.39). The reduced inhibitory potencies of the 
cis-alkene derivatives, compared to the trans-isomers, show, how important the configuration 
of only one bond is for the biological activity of these derivatives. 
To summarize this work, diverse carba-analog families of the potent and selective mGAT4 
inhibitor (S)-SNAP-5114 [(S)-24] were extensively explored. New and interesting synthetic 
methods were developed and the gathered structure-activity relation (SAR) results gave a 
deeper understanding of how changing individual structural elements affects the binding 
results. These results contribute to the final goal of finding a potent and selective inhibitor for 
mGAT4 as treatment option for patients with complex neurological disorders.  
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5. List of abbreviations  
BBB  blood-brain-barrier 
CNS  central nervous system 
EL  extracellular loop 
GABA  gamma-aminobutyric acid 
GABA-T gamma-aminobutyric acid transaminase 
GAD  glutamic acid decarboxylase 
GAT  GABA transporter 
GLU  glutamate 
GPCR  G-protein coupled receptors 
HUGO  human genome organization 
IC50  half maximal inhibitory concentration 
IL  intracellular loop 
Ki  inhibition constant 
LeuT  leucine transporter 
mGAT4 murine gamma-aminobutyric acid transporter subtype 4 
NSS  neurotransmitter-sodium-symporters 
SAR  structure-activity relationship 
SEM  standard error of the mean 
SERT  serotonin transporter 
SLC6  solute carrier 6 
SSA  succinic semialdehyde 
TM  transmembrane helix 
VGAT  vesicular neurotransmitter transporter 
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Abstract:  
To discover new, potent, and selective inhibitors for the murine gamma-aminobutyric acid 
transporter 4 (mGAT4), the structure-activity relationship (SAR) study of a new cis-alkene analog family 
based on DDPM-1457 [(S)-2], which previously showed promising inhibitory potency at and subtype 
selectivity for mGAT4, was conducted. To uncover the importance of the differences between the trans- 
and the cis-alkene moiety in the spacer, this present publication describes the synthesis of the new 
compounds ir biological results collected by 
the SAR study in our group.  
1. Introduction 
Disorders in the GABAergic neurotransmission can cause severe neurological illnesses like 
1 depression,2 epilepsy,3,4 and neuropathic pain.5 These conditions are closely 
related to the levels of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the 
central nervous system (CNS).6 GABA concentration in the synaptic cleft, amongst other factors, is 
regulated by the GABA transporter proteins (GATs).7 Four different subtypes of these membrane-bound 
proteins exist,8,9 which belong to the solute carrier 6 (SLC6) family.10,11 Depending on the species they 
are cloned from, different nomenclatures can be applied for these transporters. The Human Genome 
Organization (HUGO) denotes them as GAT1, BGT-1, GAT2, and GAT3. Alternatively, if the 
transporters are originating from mice, -1), mGAT3 
GAT3).12 mGAT1 and mGAT4 have been found to be clearly predominating in 
the CNS,13 from which mGAT1 is mainly accountable for the neuronal uptake of GABA in presynaptic 
cells and mGAT4, in particular, mediates GABA transport from the synaptic cleft into the adjacent glial 
cells.14,15 The next two subtypes (mGAT2 mGAT3) are mainly observed in the kidneys and liver16 and 
are playing no significant role in the termination of the GABAergic neurotransmission in the brain.17  
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The inhibition of mGAT1 and mGAT4 leads to elevated GABA concentrations in the synaptic cleft, 
which can be used as a treatment option in the above mentioned diverse neurological diseases. The 
highly potent and selective mGAT1 inhibitor tiagabine (5) is already in medical use, but its main 
drawbacks are the commonly observed side effects (asthenia, depression, diarrhea, dizziness, 
nervousness, and tremor).18, 19, 20 Additionally to mGAT1 selective reuptake inhibitors, a large selection 
of ligands for mGAT2 mGAT4 were identified over the last years. However, these compounds in general 
display only mediocre affinities and selectivities for their target.21, 22, 23, 24, 25 Hence, there is a need for 
more potent and subtype-selective GAT inhibitors on the one hand for mGAT2 mGAT4, but also for 
mGAT1. This would allow a more in-depth study of the physiological role of these proteins, that could 
serve as alternative treatment options for tiagabine (5), which might give rise to fewer side effects. 
(S)-SNAP-5114 [(S)-1] was the first prototypic mGAT4 inhibitor with reasonable potency at and 
selectivity for this target.26 Based on the structure of (S)-1, carba-analogs such as DDPM-1457 [(S)-2]27 
were developed, the latter of which displays a similar potency and subtype selectivity for mGAT4 as 
(S)-SNAP-5114 [(S)-1], and, in addition, a significantly enhanced chemical stability. Later on, a series 
of substances including compound 3 (Figure 1) which is similar to (S)-2, but with an alkyne spacer 
instead of a trans-alkene moiety were also synthesized. These compounds, however, showed 
significantly lower potencies at the mGATs as compared to (S)-2.28 More recently, the compound family 
represented by a trans-alkene spacer (S)-2 was expanded with analogs (4, Figure 1) by a variation of 
the triaryl moiety, i.e. by substituting one of the three aryl rings by a variety of different substituents 
(Table 1).29 Finally, as a representative of a new class of hGAT3 (  derivative 6 
is to be mentioned which represents the most potent compound of this set of inhibitors.30  
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    (S)-SNAP-5114 [(S)-1]    DDPM-1457 [(S)-2]      3   
             DDPM-1007 (rac)-2 
 
 
 
 
 
 
      4        Tiagabine (5)      6  
Figure 1. Selected GABA uptake inhibitors. For the structure of residue R see Table 1 (R = R1: a h). 
 
In this study, we aimed at the development of an additional carba-analog family of (S)-SNAP-5114 
[(S)-1] with a cis-configured alkene spacer to supplement the already published results regarding 
structure-activity relationship (SAR) of the alkyne (3, Figure 1) and the trans-alkene analogs ((S)-2 and 
4, Figure 1) and to possibly identify more potent and selective inhibitors for mGAT4. The structure of 
this new cis-alkene analog family is related to DDPM-1007 (rac-2), the racemic form of DDPM-1457 
[(S)-2], and the applied modifications are shown in Figure 2. On the one hand, the spacer between the 
nipecotic acid and the aromatic lipophilic residue should be modified by replacing the trans-alkene 
moiety by a cis-alkene unit. In addition, as a major modification, one of the aromatic moieties of the 
lipophilic triarylmethane unit should be replaced with a series of different residues, such as aromatic and 
heteroaromatic rings, benzylic residues or sterically less demanding groups (rac-7a h, Table 1). Finally, 
we intended to increase the spacer length by one methylene group either by insertion of this unit 
between the cis-alkene group and the lipophilic residue (rac-7i j, Table 1) or between the nipecotic acid 
and the cis-alkene moiety (rac-7k l, Table 1). This should uncover which linker length would be most 
beneficial regarding biological activity.  
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          DDPM-1007 (rac-2)       rac-7a h  m = 1, n = 0 
                   rac-7i j  m = 1, n = 1 
                   rac- 7k l  m = 2, n = 0 
Figure 2. General structures of targeted N-substituted nipecotic acid derivatives rac-7a l. For structures of residues R1 and R2 
see Table 1.  
 
2. Results and Discussion 
2.1. Chemistry 
As previously reported, the nipecotic acid derivatives rac-8a l displaying an alkyne unit as spacer 
(see Table 1) are easily accessible by trapping of a nipecotic acid derived iminium ion with an 
appropriate organomagnesium species.28 In the present study, the thus obtained alkyne unit comprising 
nipecotic acid derivatives rac-8a l were intended to serve as starting material for the synthesis of the 
desired target compounds rac-7a l exhibiting an alkene-based spacer with a cis-configured double 
bond. The transformation of these compounds should be accomplished by partial hydrogenation 
stereoselective reduction of alkynes to 
cis-alkenes.31, 32, 33 The conditions for the hydrogenation were briefly optimized to keep the amount of 
side products at a minimum and hence to avoid a tedious separation of the desired cis-alkenes from 
starting material and from alkanes resulting from overreduction. Two different sets of reaction conditions 
were found to serve best this purpose. In any case, first mild reaction conditions (atmospheric pressure, 
30 °C) were applied and in a separate experiment more harsh ones (30 bar, 50 °C) when the compound 
appeared to be reluctant to hydrogenation. The yields for the hydrogenation reaction ranging between 
49%  73% are listed in Table 1.  
Lastly, the carboxylic acid esters rac-9a l were subjected to hydrolysis under conditions previously 
reported for analogous compounds (12 M NaOH, MeOH) that gave the free acids rac-7a l with good to 
excellent yields (82%  98%, Table 1).28  
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Table 1. Formation of the N-substituted nipecotic acid esters rac-9a l, and their hydrolysis to the corresponding free acids 
rac-7a l. 
 
     rac-8a l28         rac-9a l         rac-7a l   
Entry Alkyne rac-8 R
1 R2 m n Ester rac-9 Conditions
a Yield %c Acid rac-7 Yield %
d 
1 rac-8a 
 
OCH3 1 0 rac-9a A 71 rac-7a 82 
2 rac-8b 
 
OCH3 1 0 rac-9b A 54 rac-7b 88 
3 rac-8c 
 
OCH3 1 0 rac-9c B 57 rac-7c 97 
4 rac-8d 
 
OCH3 1 0 rac-9d B 59 rac-7d 93 
5 rac-8e      OH OCH3 1 0 rac-9e A 73 rac-7e 83 
6 rac-8f      H OCH3 1 0 rac-9f A 57 rac-7f 98 
7 rac-8g 
 
OCH3 1 0 rac-9g B 55 rac-7g 90 
8 rac-8h 
 
OCH3 1 0 rac-9h B 64 rac-7h 88 
9 rac-8i 
 
OCH3 1 1 rac-9i A 49 rac-7i 89 
10 rac-8j 
 
H 1 1 rac-9j A 68 rac-7j 98 
11 rac-8k 
 
OCH3 2 0 rac-9k A 61 rac-7k 90 
12 rac-8l 
 
H 2 0 rac-9l A 53 rac-7l 98 
Reagents and conditions: (a) 2, EtOH, Conditions A: atmospheric pressure, 30 °C, Conditions B: 
30 bar, 50 °C; (b) 12 M NaOH, MeOH; cIsolated yield after chromatography; dIsolated yield after extraction.  
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2.2. Biological evaluation 
The synthesized N-substituted nipecotic acid derivatives with a cis-alkene spacer rac-7a l were 
evaluated for their inhibitory potencies at mGAT4 and additionally for the other murine GABA transporter 
subtypes (mGAT1 mGAT3) in a standardized [3H]GABA uptake assay based on HEK cells developed 
in our group.34 Binding affinities of these compounds towards mGAT1 (expressed in HEK cells) were 
also determined using a standardized MS Binding Assay.35 The measurements were done in triplicates 
and wherever possible, the potencies of the tested compounds in the uptake assays are given as 
pIC50 values. In cases where test compounds at a concentration of 100 µM were not able to reduce 
[3H]GABA uptake to a value of below 50%, which equals pIC50  4.00, only the percent values of 
the remaining [3H]GABA uptake are given.  
The comparison of (S)-SNAP-5114 [(S)-1] with its chemically more stable carba-analog DDPM-1457 
[(S)-2] shows that replacing the ether moiety of the spacer with a trans-alkene unit causes only minor 
differences in their binding affinity and inhibitory potencies (Table 2). As the cis-alkene analogs of the 
present study are all racemic compounds, we also included DDPM-1007 (rac-2),27 the racemic analog 
of (S)-2, in Table 2 as it appears to be the more suitable reference compound in this case. Compound 
3,28 a representative of analogs of DDPM-1007 (rac-2), with an alkyne spacer shows that the transition 
from a trans-alkene spacer to an alkyne spacer causes a significant decrease in the inhibitory potencies 
and binding affinities. Furthermore, tiagabine (5) is listed in Table 2 as a reference compound for potent 
mGAT1 inhibitors with high selectivity for this target (Table 2, entry 6).36  
Compound rac-7a presents the structural closest analog of DDPM-1007 (rac-2) in this study (Table 
3, entry 1) possessing a cis- instead of a trans-configured alkene spacer. Remarkably, this relatively 
small change of the structure results in a significant reduction of the inhibitory potencies at all mGAT 
proteins, but without loss of the selectivity in favor of mGAT4. However, compared to the 
alkyne-analog 3, the so obtained results for rac-7a shows a significant selectivity for and slightly higher 
potency at mGAT4. Similarly to rac-7a, the cis-alkene analogs rac-7b, rac-7d, and rac-7f, where one 
4-methoxyphenyl ring was replaced by a 1,3-benzodioxole, thiophene, or H substituent, respectively, 
showed, as compared to rac-2, lower potencies at all mGAT proteins combined with a slight subtype 
selectivity in favor of mGAT4. Analogs rac-7c having a thiazole ring, and rac-7e, an OH substituent 
replacing one methoxyphenyl unit of the lipophilic residue, were more or less devoid of any reasonable 
potency at all mGAT proteins. Derivatives with a benzylic residue rac-7g and rac-7h instead of one of 
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the three 4-methoxyphenyl moieties in rac-7a had greatly reduced inhibitory potencies at mGAT4, 
compared to rac-2, partly also at other mGAT proteins, the potencies at all mGATs getting very close in 
a range from about 4.0 to 4.5.  
Compounds rac-7i l gave insight on the influence of the spacer length on the inhibitory potencies at 
the different mGAT proteins. An additional methylene group between the lipophilic residue and the 
cis-alkene group resulted in a significantly lower inhibitory potency at mGAT4 for analog rac-7i having 
three 4-methoxyphenyl residues compared to rac-7a all pIC50 values being now close to 4. Surprisingly, 
compound rac-7j as an analog of rac-7i, but devoid of the three methoxy substituents, displayed a 
significantly increased potency at mGAT1 by almost 2 log units to a value of pIC50 = 6.00 ± 0.04 (Table 
3, entry 10). Also the potency at mGAT4 rose (from pIC50 = 4.21 for rac-7i to 4.82) being now almost as 
high as that of rac-7a (pIC50 = 4.99 ± 0.06, Table 3 entry 1). Hence, though the potency at mGAT1 of 
rac-7i still lays somewhat behind that of tiagabine (5) with pIC50 = 6.88 ± 0.12 (Table 2, entry 5), it 
possesses at the same time a reasonable potency at mGAT4 (pIC50 = 4.82, Table 3, entry 10). 
Compounds rac-7k and rac-7l represent analogs of rac-7i and rac-7j, respectively, the spacer extension 
being now a result of the insertion of a CH2 group adjacent to the amino function. Both compounds have 
slightly lower potencies at mGAT4 and somewhat higher potencies at mGAT1, as compared to rac-7a, 
the pIC50 values for mGAT1 mGAT3 being now in a similar range, around 4.0  4.5 and only for mGAT4 
somewhat higher (~ 4.8, Table 3, entries 11-12). Remarkably, for rac-7l, a significantly increased 
inhibitory potency could not be observed at mGAT1, as it was the case for rac-7j with the same trityl 
residue and spacer length, but the additional methylene group being in a different position.  
The binding affinities of rac-7a l determined in binding assays for mGAT1 and given as pKi values 
were in the same range as the potencies found in the uptake assays (pIC50 values) for this same 
transporter. As a general phenomenon already well known from the literature, also here the pKi values 
turned out to be about half a log unit higher than the corresponding pIC50 values.21,28,29,35 
  
- Manuscript of the third publication - 
8 
 
Table 2. Binding affinities and inhibitory potencies of reference compounds (S)-1, (S)-2, (rac)-2, 3, and 5 from the literature.  
 
 (S)-SNAP-5114 [(S)-1]    DDPM-1457 [(S)-2]       3       Tiagabine (5)  
           DDPM-1007 (rac-2)   
Entry Compound Conf. pKia 
pIC50b 
mGAT1 mGAT2 mGAT3 mGAT4 
1 (S)-SNAP-5114  [(S)-1]c S 
4.56d 
±0.02 
4.07 
±0.09 56% 
5.29 
±0.04 
5.71 
±0.07 
2 DDPM-1457  [(S)-2]c S 
4.33d 
±0.06 
4.40 
±0.05 
4.42 
±0.11 
5.47 
±0.02 
5.87 
±0.08 
3 DDPM-1007  rac-2c rac 
4.83d 
±0.04 
4.32 
±0.05 
4.68 
±0.09 
5.19 
±0.06 
5.67 
±0.06 
4 3d  rac 5.36
 
±0.02 
4.84 
 
4.36 
 
4.61 
 
4.53 
 
6 Tiagabine (5)e R 7.43 ±0.11 
6.88 
±0.12 50% 64% 73% 
aResults of the MS Binding Assays are given as pKi ± SEM; bResults of the [3H]GABA uptake assays are given as pIC50 ± SEM. 
Percentages represent remaining [3H]GABA uptake in presence of 100 µM test compound; cReference literature,27 dReference 
literature,28 eReference literature.36  
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Table 3. Binding affinities and inhibitory potencies of the N-substituted nipecotic acids with a cis-alkene spacer rac-7a l.  
 
rac-7a l 
Entry Compound (rac-7) R
1 R2 m n pKia 
pIC50b 
mGAT1 mGAT2 mGAT3 mGAT4 
1 rac-7a 
 
OCH3 1 0 4.75 4.14 65% 4.14 
4.99 
± 0.06 
2 rac-7b 
 
OCH3 1 0 4.27 4.02 4.21 4.34 
5.00 
± 0.20 
3 rac-7c 
 
OCH3 1 0 78% 69% 67% 78% 83% 
4 rac-7d 
 
OCH3 1 0 62% 4.10 4.05 49% 4.48 
5 rac-7e      OH OCH3 1 0 53% 81% 85% 97% 80% 
6 rac-7f      H OCH3 1 0 4.58 62% 68% 72% 4.31 
7 rac-7g 
 
OCH3 1 0 4.59 4.13 65% 4.01 4.24 
8 rac-7h 
 
OCH3 1 0 4.38 4.42 4.52 57% 4.20 
9 rac-7i 
 
OCH3 1 1 4.62 4.38 52% 4.07 4.21 
10 rac-7j 
 
H 1 1 6.29 ± 0.08 
6.00 
± 0.04 70% 56% 4.82 
11 rac-7k 
 
OCH3 2 0 4.63 4.51 63% 4.34 4.79 
12 rac-7l 
 
H 2 0 5.13 ± 0.11 4.39 4.26 4.10 4.76 
aResults of the MS Binding Assays are given as pKi ± SEM. For low pKi values, only one measurement was performed in triplicate, 
therefore no SEM could be calculated. Percentages represent remaining specific NO711 binding in presence of 100 µM test 
compound; bResults of the [3H]GABA uptake assays are given as pIC50 ± SEM. For low pIC50 values, only one measurement was 
performed in triplicate, therefore no SEM could be calculated. Percentages represent remaining [3H]GABA uptake in presence of 
100 µM test compound.  
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3. Conclusion 
The design and synthesis of a new cis-alkene analog family of (S)-SNAP-5114 [(S)-1] was continued 
using DDPM-1007 (rac-2) as the starting point with the aim to identify more potent and selective 
inhibitors of mGAT4.  
The synthesis of the desired cis-alkene derivatives rac-9a l was accomplished by heterogenic, 
catalytic reduction of the known alkyne-analogs rac-8a l employing . The new 
cis-alkene analogs rac-7a l, as compared to the trans-alkene isomer DDPM-1007 (rac-2), generally 
show slightly lower potencies at mGAT1 mGAT3 and significantly decreased potency at mGAT4.  
Analogs with an increased spacer length and three aromatic rings showed diverse results at mGAT1. 
Compound rac-7j having an additional methylene group between the trityl moiety and the cis-alkene unit 
exhibited surprisingly high inhibitory potency at mGAT1 (pIC50 = 6.00 ± 0.04) which was not present if 
the additional methylene group was placed between the nipecotic acid and the cis-alkene moiety 
(rac-7l, pIC50 = 4.39). 
This research revealed that by changing only the stereochemistry of the potent trans-alkene analog 
DDPM-1007 (rac-2) into a cis-alkene isomer (rac-7a) results in significantly lowered potency at mGAT4 
suggesting that the trans-double bond in the spacer plays a significant role for the biological activity of 
these analogs. 
 
  
- Manuscript of the third publication - 
11 
 
4. Experimental section 
4.1. Chemistry 
Reactions were carried out in vacuum dried glassware under argon atmosphere. All commercially 
available starting materials were used without further purification and solvents were distilled before use. 
As petroleum ether (PE) the fraction 40 60 °C was used. Flash chromatography was performed on silica 
gel (Merck 60 F-254, 0.040 0.063 mm). Medium pressure liquid chromatography (MPLC) was 
performed using a Büchi instrument (C-605 binary pump system, C-630 UV detector at 254 nm, and 
C-660 fraction collector) and a Sepacore glass column B-685 (26*230 mm) equipped with silica gel 
(YMC Gel SIL-HG, 12 nm, S-20 µm). HRMS data were obtained with JMS-GCmate II (EI, Jeol) or 
Thermo Finnigan LTQ FT Ultra (ESI, Thermo Finnigan). NMR spectra were recorded with a JNMR-GX 
(JEOL 400 or 500 MHz) or Bruker BioSpin Avance III HD (400 or 500 MHz). As an internal standard, 
the known chemical shift of solvent traces was used to reference the spectra. Spectra were processed 
using the software MestReNova. For IR spectroscopy, a Perkin Elmer FT-IR Spectrometer 1600 was 
used.  
4.2. General procedures 
4.2.1. Hydrogenation of the N-substituted nipecotic acid esters with an alkyne spacer to the 
corresponding N-substituted nipecotic acid esters with a cis-alkene spacer under standard reaction 
conditions (GP 1) 
For mild reaction conditions, 25 equiv.) was added to the solution of the ester 
with an alkyne spacer (1 equiv.) and quinoline (0.1 equiv.) in ethanol (20 mL/mmol). The flask was 
evacuated and purged with hydrogen three times and a balloon filled with hydrogen was attached to the 
sealed flask (atmospheric pressure). The mixture was stirred at 30 °C until most of the starting material 
was converted to the corresponding ester with a cis-alkene spacer, which was followed by thin layer 
chromatography (TLC) and NMR experiments. Finally, the mixture was filtered through celite, rinsed 
with Et2O, and concentrated in vacuum. The crude product was purified by flash chromatography or 
MPLC on silica gel with DCM/MeOH (99:1) or with Et2O/PE/MeOH (50:50:1). 
4.2.2. Hydrogenation of the N-substituted nipecotic acid esters with an alkyne spacer to the 
corresponding N-substituted nipecotic acid esters with a cis-alkene spacer under enhanced reaction 
conditions (GP 2) 
For the harsher 
ester with an alkyne spacer (1 equiv.) and quinoline (0.05 equiv.) in ethanol (20 mL/mmol). The pressure 
vessel was evacuated and purged with hydrogen three times and finally filled with hydrogen (30 bar). 
The mixture was stirred at 50 °C until most of the starting material was converted to the corresponding 
ester with a cis-alkene spacer which was followed by thin layer chromatography (TLC) and NMR 
experiments. Finally, the mixture was filtered through celite, rinsed with Et2O, and concentrated in 
vacuum. The crude product was purified by flash chromatography or MPLC on silica gel with 
DCM/MeOH (99:1) or with Et2O/PE/MeOH (50:50:1). 
4.2.3.  Hydrolysis of the N-substituted nipecotic acid esters (GP 3) 
The ester (1 equiv.) was dissolved in MeOH (1 mL/mmol), then an excess of NaOH (5 equiv., 12 M 
in H2O) was added dropwise at 0 °C. The mixture was stirred at 25 °C for 3 6 h until the hydrolysis was 
complete (TLC). The mixture was diluted with H2O, stirred for 1 h at 25 °C and extracted with Et2O. The 
water phase was collected and pH= 6.0 was set by adding HCl (5 equiv., 6 M in H2O) and phosphate 
buffer (pH= 6.0, 1.0 M). This solution was extracted with DCM. The combined organic layers were dried 
over Na2SO4 and concentrated under reduced pressure to get the pure product as a thick oil. To get the 
N-substituted nipecotic acid as a solid, the oil was dissolved in DCM (0.1 mL), H2O (2 mL) was added 
and an emulsion was prepared by sonication. This emulsion was freeze-dried to obtain a white, 
amorphous solid.  
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4.3. Synthesized compounds 
4.3.1. (Z)-1-[4,4,4-Tris(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7a) 
According to GP3: Ester rac-9a (40 mg, 0.070 mmol) with NaOH (0.37 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (30 mg, 82%). 
IR (KBr):  = 3428, 3032, 2998, 2934, 2834, 1717, 1700, 1606, 1580, 1507, 1464, 1396, 1295, 1250, 
1179, 1117, 1034, 915, 826, 700, 669, 638, 573 cm-1. 1  1.31 (m, 1H), 
1.42  1.65 (m, 3H), 1.73 (t, J = 11.4 Hz, 1H), 1.91 (d, J = 13.0 Hz, 1H), 2.28  2.34 (m, 3H), 2.63 (d, J 
= 9.1 Hz, 1H), 2.92 (d, J = 11.3 Hz, 1H), 3.78 (s, 9H), 5.79 (dt, J = 11.9, 5.8 Hz, 1H), 6.54 (d, J = 12.2 Hz, 
1H), 6.78  6.84 (m, 6H), 6.97  7.04 (m, 6H) ppm. 13
54.68, 55.83, 58.24, 58.36, 59.68, 114.12, 130.55, 131.98, 140.91, 141.80, 159.28, 182.65 ppm. HRMS 
(ESI): [M+H]+ calcd. for C31H36O5N, 502.2587; found 502.2586.  
4.3.2. (Z)-1-[4-(Benzo[d][1,3]dioxol-5-yl)-4,4-bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylic 
acid, (rac-7b) 
According to GP3: Ester rac-9b (42 mg, 0.080 mmol), NaOH (0.38 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (34 mg, 88%). 
IR (KBr):  = 3425, 2935, 2835, 1717, 1607, 1580, 1506, 1483, 1440, 1396, 1333, 1296, 1248, 1180, 
1119, 1097, 1036, 932, 862, 826, 811, 731, 678, 638, 569 cm-1. 1
J = 12.5, 4.0 Hz, 1H), 1.43  1.58 (m, 2H), 1.58  1.64 (m, 1H), 1.74 (t, J = 11.4 Hz, 1H), 1.91 (d, J = 
13.3 Hz, 1H), 2.26  2.40 (m, 3H), 2.65 (d, J = 9.7 Hz, 1H), 2.92 (d, J = 10.9 Hz, 1H), 3.78 (s, 6H), 5.80 
(dt, J = 11.9, 5.8 Hz, 1H), 5.90 (s, 2H), 6.52 (d, J = 12.3 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 6.58 (dd, J = 
8.2, 1.9 Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 6.80  6.84 (m, 4H), 7.00  7.04 (m, 4H) ppm. 13C NMR 
(126 
114.17, 123.96, 130.76, 131.98, 132.00, 140.59, 140.63, 141.64, 143.01, 147.21, 148.80, 159.36, 
182.61 ppm. HRMS (ESI): [M+H]+ calcd. for C31H34O6N, 516.2380; found: 516.2375. 
4.3.3. (Z)-1-[4,4-Bis(4-methoxyphenyl)-4-(thiazol-2-yl)but-2-en-1-yl]piperidine-3-carboxylic acid, 
(rac-7c) 
According to GP3: Ester rac-9c (32 mg, 0.060 mmol) NaOH (0.3 mmol, 12 M in H2O) was hydrolyzed 
to get the pure product. White solid (28 mg, 97%). 
IR (KBr):  = 3423, 2934, 2835, 1717, 1606, 1580, 1508, 1463, 1389, 1297, 1252, 1180, 1131, 1032, 
887, 865, 826, 757, 728, 669, 591, 562, 538 cm-1. 1  1.31 (m, 1H), 
1.42  1.65 (m, 3H), 1.74 (t, J = 11.4 Hz, 1H), 1.91 (d, J = 12.1 Hz, 1H), 2.26  2.34 (m, 1H), 2.34  2.42 
(m, 2H), 2.67 (d, J = 9.1 Hz, 1H), 2.93 (d, J = 10.9 Hz, 1H), 3.79 (s, 6H), 5.89 (dt, J = 11.9, 5.9 Hz, 1H), 
6.66 (d, J = 12.1 Hz, 1H), 6.84  6.89 (m, 4H), 7.06  7.12 (m, 4H), 7.49 (d, J = 3.4 Hz, 1H), 7.79 (d, J 
= 3.3 Hz, 1H) ppm. 13
114.51, 121.14, 131.63, 131.74, 138.50, 138.55, 138.95, 143.54, 160.16, 181.49, 182.62 ppm. HRMS 
(ESI): [M+H]+ calcd. for C27H31O4N2S, 479.1998; found:479.1999.  
4.3.4. (Z)-1-[4,4-Bis(4-methoxyphenyl)-4-(thiophen-3-yl)but-2-en-1-yl]piperidine-3-carboxylic acid, 
(rac-7d) 
According to GP3: Ester rac-9d (23 mg, 0.050 mmol) and NaOH (0.23 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (20 mg, 93%). 
IR (KBr):  = 2423, 2934, 2834, 1717, 1606, 1579, 1508, 1463, 1389, 1361, 1296, 1250, 1179, 1116, 
1033, 828, 795, 779, 729, 670, 652, 572 cm-1. 1 .23 (qd, J = 12.5, 4.0 Hz, 
1H), 1.43  1.57 (m, 2H), 1.58  1.63 (m, 1H), 1.73 (t, J = 11.4 Hz, 1H), 1.91 (d, J = 11.6 Hz, 1H), 2.30 
(tt, J = 11.8, 3.8 Hz, 1H), 2.34  2.41 (m, 2H), 2.64 (d, J = 10.0 Hz, 1H), 2.93 (d, J = 11.8 Hz, 1H), 3.77 
(s, 6H), 5.78 (dt, J = 12.0, 5.9 Hz, 1H), 6.48 (d, J = 12.1 Hz, 1H), 6.78 (d, J = 3.2 Hz, 2H), 6.80  6.84 
(m, 4H), 7.00  7.07 (m, 4H), 7.33  7.35 (m, 1H) ppm. 13
46.32, 54.72, 55.82, 57.47, 57.93, 58.21, 114.23, 123.93, 126.32, 130.47, 130.91, 131.42, 140.40, 
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140.44, 140.69, 150.25, 159.46, 182.63 ppm. HRMS (ESI): [M+H]+ calcd. for C28H32O4NS, 478.2046; 
found: 478.2043. 
4.3.5.  (Z)-1-[4-Hydroxy-4,4-bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7e) 
According to GP3: The ester rac-9e (45 mg, 0.10 mmol) with NaOH (0.5 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (34 mg, 83%). 
IR (KBr):  = 3201, 3000, 2931, 2832, 1607, 1583, 1507, 1454, 1389, 1342, 1304, 1247, 1174, 1102, 
1063, 1036, 983, 911, 830, 803, 766, 751, 709, 676, 636, 616, 592, 553 cm-1. 1H NMR (500 MHz, MeOD) 
J = 12.8, 3.9 Hz, 1H), 1.41 (qt, J = 12.8, 3.9 Hz, 1H), 1.55  1.62 (m, 1H), 1.79 (td, J = 11.8, 
2.8 Hz, 1H), 1.93  1.99 (m, 2H), 2.28 (tt, J = 11.8, 3.8 Hz, 1H), 2.81 (d, J = 11.4 Hz, 1H), 2.87 (dd, J = 
14.2, 6.3 Hz, 1H), 2.92 (ddd, J = 13.8, 5.7, 1.3 Hz, 1H), 3.06 (d, J = 11.3 Hz, 1H), 3.77 (s, 3H), 3.77 (s, 
3H), 5.72 (dt, J = 11.9, 5.9 Hz, 1H), 6.32 (d, J = 12.1 Hz, 1H), 6.81  6.86 (m, 4H), 7.27  7.33 (m, 
4H) ppm. 13 9.37, 46.28, 54.25, 55.77, 56.28, 57.66, 79.21, 114.21, 
114.26, 126.72, 128.87, 128.94, 141.45, 141.50, 142.81, 159.81, 159.85, 182.55 ppm. HRMS (ESI): 
[M+H]+ calcd. for C24H30NO5, 412.2118; found 412.2117. 
4.3.6.  (Z)-1-[4,4-Bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7f) 
According to GP3: Ester rac-9f (43 mg, 0.10 mmol) with NaOH (0.5 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (39 mg, 99%).  
IR (KBr):  = 3424, 2998, 2935, 2835, 1708, 1608, 1583, 1509, 1464, 1442, 1368, 1302, 1248, 1176, 
1113, 1033, 828, 815, 719, 590, 542 cm-1. 1 J = 13.0, 4.6 Hz, 1H), 
1.54 (qt, J = 12.8, 3.8 Hz, 1H), 1.62  1.70 (m, 1H), 1.86 (td, J = 11.8, 2.9 Hz, 1H), 1.96 (d, J = 12.9 Hz, 
1H), 2.06 (t, J = 11.4 Hz, 1H), 2.38 (tt, J = 11.8, 3.7 Hz, 1H), 2.85 (d, J = 11.4 Hz, 1H), 3.09  3.17 (m, 
3H), 3.75 (s, 3H), 3.76 (s, 3H), 4.91  4.93 (m, 1H), 5.65 (dt, J = 11.2, 6.7 Hz, 1H), 6.02 (t, J = 10.4 Hz, 
1H), 6.80  6.85 (m, 4H), 7.05  7.11 (m, 4H) ppm. 13
54.69, 55.77, 56.56, 58.37, 114.86, 126.32, 130.07, 130.10, 137.37, 138.07, 138.13, 159.43, 
182.72 ppm. HRMS (ESI): [M+H]+ calcd. for C24H30O4N, 396.2169; found: 396.2165.  
4.3.7. (Z)-1-[4,4,5-Tris(4-methoxyphenyl)pent-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7g) 
According to GP3: Ester rac-9g (34 mg, 0.060 mmol) with NaOH (0.3 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (28 mg, 90%). 
IR (KBr):  = 3424, 3033, 2998, 2938, 2934, 2834, 1716, 1609, 1580, 1510, 1464, 1442, 1392, 1299, 
1249, 1179, 1151, 1119, 1035, 784, 759, 745, 702, 669, 592, 550 cm-1. 1
1.21 (qd, J = 12.4, 4.6 Hz, 1H), 1.40  1.50 (m, 2H), 1.53  1.61 (m, 1H), 1.71 (t, J = 11.4 Hz, 1H), 1.90 
(d, J = 13.0 Hz, 1H), 2.29 (tt, J = 11.8, 3.8 Hz, 1H), 2.33  2.39 (m, 2H), 2.58 (d, J = 6.4 Hz, 1H), 2.90 
(d, J = 9.9 Hz, 1H), 3.44 (s, 2H), 3.70 (s, 3H), 3.78 (s, 3H), 3.78 (s, 3H), 5.61 (dt, J = 12.1, 6.0 Hz, 1H), 
6.12 (dt, J = 12.2, 2.2 Hz, 1H), 6.58  6.65 (m, 4H), 6.79  6.85 (m, 4H), 7.12  7.18 (m, 4H) ppm. 13C 
114.20, 129.43, 131.00, 131.05, 131.23, 133.01, 138.86, 140.53, 140.62, 159.27, 159.29, 159.47, 
182.58 ppm. HRMS (ESI): [M+H]+ calcd. for C32H38NO5, 516.2744; found: 516.2736. 
4.3.8.  (Z)-1-[4,4-Bis(4-methoxyphenyl)-5-phenylpent-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7h) 
According to GP3: Ester rac-9h (21 mg, 0.040 mmol) with NaOH (0.2 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (17 mg, 88%). 
IR (KBr):  = 3429, 3025, 2995, 2934, 2835, 1715, 1607, 1579, 1509, 1454, 1396, 1290, 1250, 1181, 
1151, 1118, 1034, 830, 767, 734, 702, 668, 600, 565 cm-1. 1 J = 
12.2, 4.3 Hz, 1H), 1.41  1.50 (m, 2H), 1.53  1.61 (m, 1H), 1.71 (t, J = 11.5 Hz, 1H), 1.90 (d, J = 13.3 Hz, 
1H), 2.29 (tt, J = 11.8, 3.7 Hz, 1H), 2.36 (d, J = 5.7 Hz, 3H), 2.58 (d, J = 7.1 Hz, 1H), 2.90 (d, J = 11.0 Hz, 
1H), 3.50 (s, 2H), 3.78 (s, 3H), 3.78 (s, 3H), 5.61 (dt, J = 12.2, 6.0 Hz, 1H), 6.12 (dt, J = 12.2, 2.2 Hz, 
1H), 6.70  6.74 (m, 2H), 6.79  6.85 (m, 4H), 7.00  7.10 (m, 3H), 7.12  7.19 (m, 4H) ppm. 13C NMR 
9, 53.30, 54.53, 55.78, 57.46, 58.20, 114.22, 127.06, 
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128.28, 129.53, 130.97, 131.01, 132.12, 138.71, 139.26, 140.49, 140.59, 159.29, 182.59 ppm. HRMS 
(ESI): [M+H]+ calcd. for C31H36O4N 486.2638; found 486.2635. 
4.3.9.  (Z)-1-[5,5,5-Tris(4-methoxyphenyl)pent-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7i) 
According to GP3: Ester rac-9i (29 mg, 0.050 mmol) with NaOH (0.25 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (23 mg, 89%). 
IR (KBr):  = 3424, 3034, 2998, 2934, 2834, 1717, 1607, 1580, 1508, 1463, 1441, 1387, 1295, 1249, 
1182, 1119, 1035, 823, 577 cm-1. 1 J = 12.6, 4.1 Hz, 1H), 1.42  
1.58 (m, 1H), 1.59  1.69 (m, 1H), 1.73 (td, J = 11.9, 2.7 Hz, 1H), 1.89  1.97 (m, 1H), 1.98 (t, J = 
11.4 Hz, 1H), 2.34 (tt, J = 11.7, 3.7 Hz, 1H), 2.68 (d, J = 11.2 Hz, 1H), 2.79  2.94 (m, 2H), 3.05 (d, J = 
11.5 Hz, 1H), 3.23  3.29 (m, 1H), 3.32  3.39 (m, 1H), 3.76 (s, 9H), 5.39 (dt, J = 12.0, 6.6 Hz, 1H), 5.49 
(dt, J = 12.3, 6.3 Hz, 1H), 6.75  6.84 (m, 6H), 7.03  7.12 (m, 6H). 13
29.30, 40.40, 46.45, 54.59, 55.70, 55.78, 56.71, 58.26, 114.05, 127.72, 131.31, 131.97, 141.18, 159.04, 
182.76. HRMS (ESI): [M+H]+ calcd. for C32H38O5N, 516.2744; found: 516.2742. 
4.3.10. (Z)-1-[5,5,5-Triphenylpent-2-en-1-yl]piperidine-3-carboxylic acid, (rac-7j) 
According to GP3: The ester rac-9j (56 mg, 0.12 mmol) with NaOH (0.6 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (50 mg, 98%). 
IR (KBr):  = 3054, 3027, 2937, 2859, 2788, 1952, 1887, 1709, 1595, 1492, 1467, 1445, 1388, 1338, 
1304, 1269, 1188, 1135, 1103, 1035, 1001, 961, 866, 760, 749, 700, 625, 613, 521 cm-1. 1H NMR 
(500 J = 12.8, 4.2 Hz, 1H), 1.50 (qt, J = 13.0, 3.9 Hz, 1H), 1.61  1.67 (m, 1H), 
1.76 (td, J = 11.9, 2.9 Hz, 1H), 1.92  2.00 (m, 2H), 2.35 (tt, J = 11.8, 3.7 Hz, 1H), 2.70 (d, J = 11.4 Hz, 
1H), 2.79  2.91 (m, 2H), 3.04 (d, J = 11.3 Hz, 1H), 3.43 (qd, J = 15.4, 6.5 Hz, 2H), 5.36  5.43 (m, 1H), 
5.45  5.52 (m, 1H), 7.15  7.28 (m, 15H) ppm. 13C 
51.50, 59.70, 61.69, 62.71, 63.26, 132.10, 133.08, 133.84, 135.45, 136.56, 153.52, 187.68 ppm. HRMS 
(ESI): [M+H]+ calcd. for C29H32O2N, 426.2427; found 426.2437. 
4.3.11.  (Z)-1-[5,5,5-Tris(4-methoxyphenyl)pent-3-en-1-yl]piperidine-3-carboxylic acid, (rac-7k) 
According to GP3: Ester rac-9k (40 mg, 0.070 mmol) with NaOH (0.36 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (23 mg, 89%). 
IR (KBr):  = 3448, 2998, 2934, 2834, 1717, 1606, 1579, 1507, 1463, 1442, 1399, 1294, 1249, 1178, 
1117, 1034, 915, 826, 79, 707, 669, 637, 609, 571 cm-1. 1 J = 12.6, 
3.8 Hz, 1H), 1.43 (qt, J = 12.5, 3.5 Hz, 1H), 1.52  1.63 (m, 2H), 1.68  1.76 (m, 2H), 1.83 (t, J = 11.4 Hz, 
1H), 1.89 (d, J = 13.0 Hz, 1H), 1.97  2.07 (m, 1H), 2.07  2.17 (m, 1H), 2.27 (tt, J = 11.8, 3.7 Hz, 1H), 
2.44 (d, J = 11.1 Hz, 1H), 2.81 (d, J = 11.0 Hz, 1H), 3.77 (s, 9H), 5.59 (dt, J = 11.7, 7.4 Hz, 1H), 6.46 (d, 
J = 11.7 Hz, 1H), 6.76  6.82 (m, 6H), 6.96  7.03 (m, 6H) ppm. 13
27.67, 29.36, 46.28, 54.32, 55.79, 58.17, 58.63, 59.63, 114.07, 131.72, 131.96, 141.56, 141.65, 159.19, 
182.71 ppm. HRMS (ESI): [M+H]+ calcd. for C32H38O5N, 516.2744; found: 516.2739. 
4.3.12. (Z)-1-[5,5,5-Triphenylpent-3-en-1-yl]piperidine-3-carboxylic acid, (rac-7l) 
According to GP3: The ester rac-9l (51 mg, 0.11 mmol) with NaOH (0.55 mmol, 12 M in H2O) was 
hydrolyzed to get the pure product. White solid (46 mg, 98%). 
IR (KBr):  = 3427, 3055, 3019, 2938, 2858, 2804, 1711, 1594, 1490, 1445, 1395, 1301, 1186, 1154, 
1103, 1088, 1033, 1001, 930, 901, 871, 757, 701, 667, 600, 526 cm-1. 1H 
1.22 (qd, J = 12.8, 4.2 Hz, 1H), 1.42 (qt, J = 12.9, 3.8 Hz, 1H), 1.52  1.62 (m, 2H), 1.68  1.74 (m, 2H), 
1.78 (t, J = 11.4 Hz, 1H), 1.88 (d, J = 12.8 Hz, 1H), 2.04 (qt, J = 12.3, 7.0 Hz, 2H), 2.25 (tt, J = 11.8, 
3.7 Hz, 1H), 2.44 (d, J = 11.1 Hz, 1H), 2.76 (d, J = 11.1 Hz, 1H), 5.67 (dt, J = 11.7, 7.4 Hz, 1H), 6.54 (dt, 
J = 11.6, 1.8 Hz, 1H), 7.11  7.29 (m, 15H) ppm. 13
46.31, 54.38, 58.10, 58.43, 61.62, 127.19, 128.84, 131.10, 132.59, 141.10, 148.97, 182.71 ppm. HRMS 
(ESI): [M+H]+ calcd. for C29H32O2N, 426.2427; found 426.2424. 
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4.3.13. Ethyl (Z)-1-[4,4,4-tris(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylate, (rac-9a) 
According to GP1: Ester rac-8a 
(85 mg, 0.040 mmol) in ethanol (10 mL). The crude product was purified by flash chromatography with 
DCM/MeOH (99:1). Yellow oil (150 mg, 71%). 
IR (Film):  = 2937, 2833, 2794, 1728, 1606, 1580, 1506, 1463, 1294, 1248, 1178, 1151, 1134, 1098, 
1035, 826 cm-1. 1H NMR (500 MHz, CD2Cl2 J = 7.1 Hz, 3H), 1.27  1.37 (m, 1H), 1.39  1.49 
(m, 1H), 1.57  1.64 (m, 1H), 1.69 (td, J = 11.2, 2.8 Hz, 1H), 1.76  1.90 (m, 2H), 2.29 (dd, J = 6.1, 
2.2 Hz, 2H), 2.41 (tt, J = 10.3, 3.8 Hz, 1H), 2.46 (d, J = 10.4 Hz, 1H), 2.65 (d, J = 11.1 Hz, 1H), 3.77 (s, 
9H), 4.08 (q, J = 7.1 Hz, 2H), 5.74 (dt, J = 12.1, 6.0 Hz, 1H), 6.48 (dt, J = 12.1, 2.2 Hz, 1H), 6.75  6.80 
(m, 6H), 7.01  7.06 (m, 6H) ppm. 13C NMR (126 MHz, CD2Cl2
55.73, 55.97, 57.44, 58.87, 60.66, 113.49, 131.34, 131.81, 140.40, 158.32, 174.48 ppm. HRMS (EI): 
[M]+ calcd. for C33H39O5N, 529.2828; found: 529.2817. 
4.3.14. Ethyl (Z)-1-[4-(benzo[d][1,3]dioxol-5-yl)-4,4-bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-
carboxylate, (rac-9b) 
According to GP2: Ester rac-8b 
catalyst (40 mg, 0.019 mmol) in ethanol (4 mL). The crude product was purified by MPLC with 
DCM/MeOH (98:2). Yellow oil (22 mg, 54%). 
IR (Film):  = 2939, 2900, 2835, 2782, 1729, 1607, 1579, 1506, 1483, 1465, 1440, 1299, 1248, 1180, 
1151, 1134, 1098, 1037, 935, 862, 826, 810, 732, 699, 677 cm-1. 1H NMR (500 MHz, CD2Cl2
J = 7.1 Hz, 3H), 1.27  1.37 (m, 1H), 1.40  1.49 (m, 1H), 1.57  1.64 (m, 1H), 1.66  1.74 (m, 1H), 1.77 
 1.89 (m, 2H), 2.31 (d, J = 3.9 Hz, 2H), 2.42 (tt, J = 10.3, 3.9 Hz, 1H), 2.48 (d, J = 10.8 Hz, 1H), 2.66 
(d, J = 11.2 Hz, 1H), 3.77 (s, 6H), 4.08 (q, J = 7.1 Hz, 2H), 5.75 (dt, J = 12.1, 6.0 Hz, 1H), 5.92 (s, 2H), 
6.46 (dt, J = 12.1, 2.2 Hz, 1H), 6.59  6.62 (m, 2H), 6.68 (d, J = 8.9 Hz, 1H), 6.76  6.80 (m, 4H), 7.02 
 7.07 (m, 4H) ppm. 13C NMR (126 MHz, CD2Cl2
57.42, 59.32, 60.68, 101.72, 107.54, 111.21, 113.53, 123.32, 131.36, 131.94, 140.09, 140.16, 140.34, 
142.49, 146.26, 147.94, 158.40, 174.49 ppm. HRMS (ESI): [M+H]+ calcd. for C33H38NO6, 544.2693; 
found: 544.2689. 
4.3.15. Ethyl (Z)-1-[4,4-bis(4-methoxyphenyl)-4-(thiazol-2-yl)but-2-en-1-yl]piperidine-3-carboxylate, 
(rac-9c) 
According to GP2: Ester rac-8c (67 mg, 0.13 mmol), quinoline (2 mg, 0.01 mmo
catalyst (70 mg, 0.033 mmol) in ethanol (4 mL). The crude product was purified by MPLC with 
DCM/MeOH (97:3). Yellow oil (38 mg, 58%).  
IR (Film):  = 2936, 2829, 1727, 1606, 1579, 1508, 1461, 1440, 1384, 1298, 1251, 1180, 1148, 1130, 
1097, 1032, 890, 861, 825, 719, 668 cm-1. 1H NMR (500 MHz, CD2Cl2 J = 7.2 Hz, 3H), 1.29 
 1.37 (m, 1H), 1.40  1.50 (m, 1H), 1.56  1.67 (m, 1H), 1.68  1.76 (m, 1H), 1.77  1.84 (m, 1H), 1.84 
 1.92 (m, 1H), 2.30  2.39 (m, 2H), 2.40  2.46 (m, 1H), 2.49 (d, J = 10.2 Hz, 1H), 2.68 (d, J = 10.0 Hz, 
1H), 3.79 (s, 6H), 4.08 (q, J = 7.1 Hz, 2H), 5.83 (dt, J = 12.0, 6.0 Hz, 1H), 6.65 (d, J = 12.1 Hz, 1H), 6.79 
 6.83 (m, 4H), 7.10  7.15 (m, 4H), 7.27 (d, J = 3.3 Hz, 1H), 7.77 (d, J = 3.3 Hz, 1H) ppm. 13C NMR 
(101 MHz, CD2Cl2  57.25, 59.23, 60.68, 113.74, 
119.84, 131.05, 132.71, 138.01, 138.28, 138.35, 143.25, 159.08, 174.47, 179.78 ppm. HRMS (ESI): 
[M+H]+ calcd. for C29H35O4N2S 507.2312; found: 507.2313. 
4.3.16. Ethyl (Z)-1-[4,4-bis(4-methoxyphenyl)-4-(thiophen-3-yl)but-2-en-1-yl]piperidine-3-
carboxylate, (rac-9d) 
According to GP2: Ester rac-8d 
catalyst (32 mg, 0.015 mmol) in ethanol (3 mL). The crude product was purified by MPLC with 
DCM/MeOH (98:2). Yellow oil (15 mg, 59%).  
IR (Film):  = 2927, 2853, 1729, 1607, 1578, 1508, 1459, 1375, 1297, 1249, 1180, 1151, 1116, 1099, 
1034, 828, 793, 782, 669, 654 cm-1. 1H NMR (500 MHz, CD2Cl2 J = 7.1 Hz, 3H), 1.27  1.38 
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(m, 1H), 1.39  1.50 (m, 1H), 1.57  1.64 (m, 1H), 1.65  1.74 (m, 1H), 1.76  1.91 (m, 2H), 2.33 (d, J = 
4.8 Hz, 2H), 2.42 (tt, J = 10.2, 3.8 Hz, 1H), 2.47 (d, J = 10.6 Hz, 1H), 2.67 (d, J = 10.1 Hz, 1H), 3.77 (s, 
6H), 4.08 (q, J = 7.1 Hz, 2H), 5.74 (dt, J = 12.1, 6.0 Hz, 1H), 6.42 (dt, J = 12.1, 2.2 Hz, 1H), 6.77  6.81 
(m, 6H), 7.04  7.08 (m, 4H), 7.26 (dd, J = 5.1, 3.0 Hz, 1H) ppm. 13C NMR (126 MHz, CD2Cl2
25.12, 27.26, 42.45, 54.11, 55.74, 55.97, 56.69, 57.03, 60.67, 113.61, 123.50, 125.61, 130.45, 130.78, 
131.75, 139.33, 139.86, 139.92, 149.63, 158.52, 174.48 ppm. HRMS (ESI): [M+H]+ calcd. for 
C30H36NO4S, 506.2359; found: 506.2354.  
4.3.17. Ethyl (Z)-1-[4-hydroxy-4,4-bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylate, 
(rac-9e) 
According to GP1: Ester rac-8e 
catalyst (45 mg, 0.021 mmol) in ethanol (2 mL). The reaction time was 20 min. The crude product was 
purified by flash chromatography with Et2O/PE/MeOH (50:50:2). Yellow oil (45 mg, 73%). 
IR (Film):  = 2938, 2833, 1729, 1607, 1583, 1506, 1465, 1440, 1301, 1246, 1171, 1151, 1131, 1086, 
1034, 1000, 914, 829, 692, 668 cm-1. 1H NMR (500 MHz, CDCl3 J = 7.1 Hz, 3H), 1.23  1.35 
(m, 1H), 1.36  1.46 (m, 1H), 1.56  1.65 (m, 1H), 1.83  2.02 (m, 3H), 2.29 (tt, J = 11.3, 3.8 Hz, 1H), 
2.83 (d, J = 11.1 Hz, 1H), 2.89 (ddd, J = 13.7, 6.0, 1.1 Hz, 1H), 2.99 (ddd, J = 13.7, 5.5, 1.4 Hz, 1H), 
3.07 (d, J = 11.1 Hz, 1H), 3.77 (s, 3H), 3.78 (s, 3H), 4.08 (qd, J = 7.1, 1.8 Hz, 2H), 5.65 (dt, J = 11.8, 
5.7 Hz, 1H), 6.38 (d, J = 12.2 Hz, 1H), 6.78  6.83 (m, 4H), 7.32  7.38 (m, 4H), 8.71 (s, 1H) ppm. 13C 
NMR (126 MHz, CDCl3 , 55.06, 55.32, 55.36, 60.50, 77.76, 
113.35, 113.39, 123.68, 127.63, 127.69, 140.96, 141.00, 143.12, 158.27, 158.32, 173.82 ppm. HRMS 
(EI): [M]+ calcd. for C26H33O5N 439.2359; found 439.2361. 
4.3.18. Ethyl (Z)-1-[4,4-bis(4-methoxyphenyl)but-2-en-1-yl]piperidine-3-carboxylate, (rac-9f) 
According to GP1: Ester rac-8f 
catalyst (54 mg, 0.025 mmol) in ethanol (3 mL). The crude product was purified by flash chromatography 
with DCM/MeOH (99:1). Yellow oil (60 mg, 57%). 
IR (Film):  = 2936, 1728, 1674, 1609, 1577, 1508, 1465, 1437, 1301, 1247, 1176, 1148, 1097, 1034, 
908, 826, 728 cm-1. 1H NMR (400 MHz, CDCl3 J = 7.1 Hz, 3H), 1.42 (qd, J = 12.0, 4.0 Hz, 
1H), 1.51  1.63 (m, 1H), 1.65  1.75 (m, 1H), 1.89  2.01 (m, 2H), 2.13 (t, J = 10.7 Hz, 1H), 2.50  2.60 
(m, 1H), 2.78 (d, J = 11.2 Hz, 1H), 3.01 (d, J = 11.3 Hz, 1H), 3.13 (dd, J = 6.8, 1.7 Hz, 2H), 3.77 (s, 3H), 
3.78 (s, 3H), 4.11 (q, J = 7.1 Hz, 2H), 4.92 (d, J = 9.9 Hz, 1H), 5.65 (dt, J = 10.9, 6.7 Hz, 1H), 5.98 (t, J 
= 10.4 Hz, 1H), 6.79  6.85 (m, 4H), 7.05  7.11 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3
24.73, 27.03, 42.08, 47.08, 53.89, 55.38, 55.67, 55.70, 60.44, 113.97, 126.49, 129.21, 135.74, 136.76, 
158.11, 174.24 ppm. HRMS (ESI): [M+H]+ calcd. for C26H34O4N, 424.2482; found: 424.2477. 
4.3.19. Ethyl (Z)-1-[4,4,5-tris(4-methoxyphenyl)pent-2-en-1-yl]piperidine-3-carboxylate, (rac-9g) 
According to GP2: Ester rac-8g 
catalyst (53 mg, 0.025 mmol) in ethanol (3 mL). The crude product was purified by MPLC with 
DCM/MeOH (98:2). Yellow oil (30 mg, 55%). 
IR (Film):  = 2935, 2829, 1729, 1609, 1579, 1511, 1467, 1440, 1372, 1301, 1249, 1179, 1151, 1109, 
1035, 828, 775, 668 cm-1. 1H NMR (500 MHz, CD2Cl2 J = 7.1 Hz, 3H), 1.25  1.36 (m, 1H), 
1.38  1.47 (m, 1H), 1.55  1.68 (m, 2H), 1.75  1.83 (m, 2H), 2.32 (dd, J = 6.1, 2.1 Hz, 2H), 2.37  2.47 
(m, 2H), 2.64 (d, J = 11.3 Hz, 1H), 3.44 (s, 2H), 3.71 (s, 3H), 3.78 (s, 6H), 4.07 (q, J = 7.1 Hz, 2H), 5.59 
(dt, J = 12.3, 6.2 Hz, 1H), 6.07 (dt, J = 12.1, 2.1 Hz, 1H), 6.58  6.62 (m, 2H), 6.63  6.67 (m, 2H), 6.76 
 6.81 (m, 4H), 7.13  7.17 (m, 4H) ppm. 13C NMR (126 MHz, CD2Cl2
47.59, 52.55, 54.04, 55.55, 55.72, 55.91, 56.64, 60.66, 113.16, 113.59, 130.22, 130.57, 130.74, 132.46, 
137.44, 140.02, 140.08, 158.29, 158.58, 174.49 ppm. HRMS (EI): [M+H]+ calcd. for C34H42O5N, 
544.3058; found: 544.3059. 
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4.3.20. Ethyl (Z)-1-[4,4-bis(4-methoxyphenyl)-5-phenylpent-2-en-1-yl]piperidine-3-carboxylate, 
(rac-9h) 
According to GP2: Ester rac-8h 
catalyst (32 mg, 0.015 mmol) in ethanol (3 mL). The crude product was purified by MPLC with 
DCM/MeOH (98:2). Yellow oil (20 mg, 64%). 
IR (Film):  = 2938, 2835, 1730, 1677, 1607, 1579, 1509, 1454, 1372, 1290, 1249, 1181, 1150, 1097, 
1034, 858, 829, 804, 757, 733, 702, 668 cm-1. 1H NMR (500 MHz, CD2Cl2 J = 7.1 Hz, 3H), 
1.26  1.36 (m, 1H), 1.38  1.48 (m, 1H), 1.56  1.62 (m, 1H), 1.66 (t, J = 10.8 Hz, 1H), 1.76  1.84 (m, 
2H), 2.33 (dd, J = 6.2, 2.2 Hz, 2H), 2.37  2.47 (m, 2H), 2.65 (d, J = 10.6 Hz, 1H), 3.51 (s, 2H), 3.78 (s, 
6H), 4.07 (q, J = 7.1 Hz, 2H), 5.60 (dt, J = 12.2, 6.1 Hz, 1H), 6.09 (dt, J = 12.2, 2.2 Hz, 1H), 6.74  6.77 
(m, 2H), 6.77  6.81 (m, 4H), 7.04  7.12 (m, 3H), 7.14  7.18 (m, 4H) ppm. 13C NMR (126 MHz, CD2Cl2) 
 60.66, 113.61, 126.50, 127.79, 
130.18, 130.89, 131.61, 137.27, 138.73, 140.01, 140.07, 158.32, 174.50 ppm. HRMS (EI): [M]+ calcd. 
for C33H39O4N, 513.2879; found 513.2880. 
4.3.21. Ethyl (Z)-1-[5,5,5-tris(4-methoxyphenyl)pent-2-en-1-yl]piperidine-3-carboxylate, (rac-9i) 
According to GP1: Ester rac-8i 
catalyst (64 mg, 0.030 mmol) in ethanol (2 mL). The crude product was purified by flash chromatography 
with DCM/MeOH (98:2). Yellow oil (40 mg, 49%). 
IR (Film):  = 2937, 2835, 1728, 1676, 1607, 1579, 1509, 1464, 1441, 195, 1250, 1182, 1152, 1035, 
826, 734 cm-1. 1H NMR (400 MHz, CD2Cl2 J = 7.1 Hz, 3H), 1.34  1.57 (m, 2H), 1.62  1.72 
(m, 1H), 1.81  1.95 (m, 2H), 2.09 (t, J = 10.5 Hz, 1H), 2.49 (tt, J = 10.2, 3.8 Hz, 1H), 2.60 (d, J = 11.3 Hz, 
1H), 2.82  2.89 (m, 1H), 2.89 (d, J = 5.1 Hz, 2H), 3.23  3.40 (m, 2H), 3.77 (s, 9H), 4.09 (q, J = 7.1 Hz, 
2H), 5.33  5.45 (m, 2H), 6.75  6.82 (m, 6H), 7.06  7.13 (m, 6H) ppm. 13C NMR (101 MHz, CD2Cl2
14.60, 25.20, 27.49, 39.88, 42.53, 54.25, 54.99, 55.69, 56.16, 56.31, 60.69, 113.51, 128.73, 130.26, 
130.71, 140.51, 158.20, 174.55 ppm. HRMS (EI): [M]+ calcd. for C34H41O5N, 543.2985; found: 543.2964. 
4.3.22. Ethyl (Z)-1-[5,5,5-triphenylpent-2-en-1-yl]piperidine-3-carboxylate, (rac-9j) 
According to GP1: Ester rac-8j 
catalyst (51 mg, 0.024 mmol) in ethanol (2 mL). The crude product was purified by flash chromatography 
with Et2O/PE/MeOH (50:50:0.5). Yellow oil (37 mg, 68%). 
IR (Film):  = 3056, 3021, 2937, 2853, 2788, 1730, 1595, 1492, 1445, 1374, 1306, 1217, 1179, 1150, 
1133, 1100, 1032, 855, 801, 759, 700, 669 cm- 1. 1H NMR (400 MHz, CD2Cl2 J = 7.1 Hz, 3H), 
1.36  1.56 (m, 2H), 1.64  1.71 (m, 1H), 1.84  1.94 (m, 2H), 2.08 (t, J = 10.5 Hz, 1H), 2.49 (tt, J = 
10.3, 3.8 Hz, 1H), 2.60 (d, J = 11.8 Hz, 1H), 2.82  2.89 (m, 3H), 3.37  3.48 (m, 2H), 4.10 (q, J = 7.1 Hz, 
2H), 5.35  5.45 (m, 2H), 7.18  7.30 (m, 15H) ppm. 13C NMR (101 MHz, CD2Cl2
39.45, 42.56, 54.27, 56.17, 56.25, 57.03, 60.69, 126.52, 128.36, 129.13, 129.80, 129.88, 147.88, 
174.56 ppm. HRMS (EI): [M]+ calcd. for C31H35O2N, 453.2668; found: 453.2650. 
4.3.23. Ethyl (Z)-1-[5,5,5-tris(4-methoxyphenyl)pent-3-en-1-yl]piperidine-3-carboxylate, (rac-9k) 
According to GP1: Ester rac-8k 
catalyst (64 mg, 0.030 mmol) in ethanol (3 mL). The crude product was purified by flash chromatography 
with DCM/MeOH (99:1). Yellow oil (50 mg, 61%). 
IR (Film):  = 2938, 2834, 2807, 1729, 1606, 1579, 1506, 1464, 1442, 1370, 1297, 1249, 1178, 1151, 
1116, 1035, 914, 826, 703, 668, 572 cm-1. 1H NMR (400 MHz, CD2Cl2 J = 7.1 Hz, 3H), 1.29 
 1.49 (m, 2H), 1.56  1.65 (m, 3H), 1.75 (td, J = 10.9, 2.9 Hz, 1H), 1.79  1.86 (m, 1H), 1.92 (t, J = 
10.6 Hz, 1H), 2.01  2.13 (m, 2H), 2.37  2.46 (m, 2H), 2.66 (d, J = 10.9 Hz, 1H), 3.77 (s, 9H), 4.08 (q, 
J = 7.2 Hz, 2H), 5.64 (dt, J = 11.7, 7.3 Hz, 1H), 6.42 (dt, J = 11.8, 1.9 Hz, 1H), 6.76  6.81 (m, 6H), 7.02 
 7.07 (m, 6H) ppm. 13C NMR (101 MHz, CD2Cl2
55.70, 56.07, 58.16, 58.91, 113.47, 131.34, 132.11, 139.94, 140.86, 158.26, 174.57 ppm. HRMS (EI): 
[M-H]+ calcd. for C34H40O5N, 542.2912; found: 542.2900. 
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4.3.24. Ethyl (Z)-1-[5,5,5-triphenylpent-3-en-1-yl]piperidine-3-carboxylate, (rac-9l) 
According to GP1: Ester rac-8l 
catalyst (73 mg, 0.034 mmol) in ethanol (4 mL). The crude product was purified by flash chromatography 
with DCM/MeOH (99:1). Yellow oil (41 mg, 53%). 
IR (Film):  = 3057, 3019, 2978, 2940, 2853, 2806, 1731, 1594, 1490, 1467, 1445, 1370, 1311, 1271, 
114, 1179, 1151, 1134, 1103, 1033, 1001, 964, 931, 901, 862, 752, 701, 667 cm- 1. 1H NMR (500 MHz, 
CD2Cl2 J = 7.1 Hz, 3H), 1.28  1.37 (m, 1H), 1.37  1.46 (m, 1H), 1.55  1.63 (m, 3H), 1.73 
(td, J = 10.9, 3.0 Hz, 1H), 1.78  1.84 (m, 1H), 1.88 (t, J = 10.6 Hz, 1H), 1.98  2.07 (m, 2H), 2.36  2.43 
(m, 2H), 2.62 (d, J = 11.1 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 5.70 (dt, J = 11.7, 7.3 Hz, 1H), 6.49 (dt, J = 
11.7, 2.0 Hz, 1H), 7.16  7.21 (m, 9H), 7.24  7.28 (m, 6H) ppm. 13C NMR (126 MHz, CD2Cl2
25.13, 27.49, 27.70, 42.47, 53.99, 55.99, 57.91, 60.63, 60.92, 126.48, 128.29, 130.50, 132.94, 139.48, 
148.28, 174.57 ppm. HRMS (EI): [M-H]+ calcd. for C31H34O2N, 452.2595; found: 452.2573. 
 
4.4. Biological evaluation 
4.4.1.  MS Binding Assays 
The MS Binding Assays were performed with mGAT1 membrane preparations obtained from a stable 
HEK293 cell line and NO711 as non labeled marker in competitive binding experiments as described 
previously.35  
4.4.2.  GABA uptake assay 
The [3H]GABA uptake assays were performed in a 96-well plate format with intact HEK293 cells stably 
expressing mGAT1, mGAT2, mGAT3, mGAT4 as described earlier.34  
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